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ABSTRACT 
COSTS AND USE OF ORAL ANTI-CANCER MEDICATIONS AMONG SENIOR 
MEDICARE PART D BENEFICIARIES 
By Nantana Kaisaeng, Ph.D. 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
Virginia Commonwealth University, 2012 
Advisor: Norman V. Carroll, Professor 
 Department of Pharmacotherapy and Outcomes Science, School of Pharmacy 
 
Oral cancer drugs are branded and expensive medications that generally do not 
have generics available.
 
The restrictions of the Medicare Part D program, including the 
coverage gap and high cost-sharing, and the high cost of oral chemotherapy may lead to 
patients’ non-adherence to medication. Few studies have examined the cost and 
utilization of oral anti-cancer medications. This study will be the first to examine the 
costs associated with the use of oral anti-cancer medications and the impact of cost-
sharing and type of prescription drug subsidy on medication discontinuation in the 
Medicare Part D elderly population. 
Objectives: To determine the usage and costs of oral cancer treatment in elderly 
Medicare Part D beneficiaries and to examine the relationship between out of pocket 
costs and medication discontinuation or delay. 
 Methods: A cross-sectional study of the spending and usage of oral cancer drugs 
in the Medicare Part D population was conducted. A 5% random sample of 2008 
Medicare beneficiaries was used. The study sample included all members of this group 
who: 1) were 65 years of age and older and 2) filled at least one prescription for imatinib, 
xv 
 
erlotinib, anastrozole, letrozole, or thalidomide. We examined the average costs patients 
paid per day, the cost that the Part D plan paid per day, and the total cost that patients 
paid for the entire year for each drug. The demographic characteristics and type of 
prescription drug subsidy of Part D beneficiaries who used oral cancer drugs were 
reported in frequency counts and percentages. We also determined the percentage of 
enrollees who entered the Part D coverage gap, the time and duration that they fell into 
the coverage gap, the number of beneficiaries who discontinued treatment and the 
association between OOP costs and medication discontinuation or delay, controlling for 
polypharmacy, prescription coverage and socio-demographic factors. 
Results: Prescription drug subsidy was categorized in four groups: 1) Dual 
Eligible (DE), 2) full Low Income Subsidy (LIS), 3) partial LIS, and 4) no subsidy. Mean 
out-of-pocket (OOP) costs per day were between $0.03 and $0.09 for DE beneficiaries, 
between $0.04 and $0.23 for full LIS beneficiaries, between $1.17 and $6.34 for partial 
LIS beneficiaries and between $2.93 and $36.84 for beneficiaries who did not receive a 
subsidy. On average, the beneficiaries who used oral cancer medications were between 
75 and 76 years of age. Over half of oral cancer medication users were Caucasian and 
female. Over two-thirds of oral cancer medication users received no subsidies for their 
prescription coverage. About 99% of users of the more expensive drugs - imatinib, 
erlotinib and thalidomide - entered the coverage gap and the majority of these entered the 
coverage gap at the time of their first fill. In contrast, beneficiaries who filled the less 
expensive drugs - anastrozole and letrozole - entered the coverage gap later. Less than 
7% entered the coverage gap at the time of the first fill of their prescriptions. 
Beneficiaries who used imatinib, erlotinib, or thalidomide spent approximately a month 
xvi 
 
in the coverage gap. Over the course of a year, the majority of their time was spent in the 
catastrophic phase. Approximately 33-60% of total oral cancer drug users discontinued 
their therapies. About 50% of these discontinued during the coverage gap for anastrozole 
and letrozole and about 80% discontinued during the catastrophic phase for imatinib, 
erloinib and thalidomide. OOP costs were associated with medication discontinuation for 
all five oral cancer drugs. The odds of discontinuation and delay increased 101%, 170%, 
and 264% for each $100 increase in OOP spending for imatinib, erlotinib and 
thalidomide users, respectively. The odds of discontinuation and delay increased 9%-
10%, and 6-8% for every $10 increase in OOP spending for anastrozole and letrozole 
users, respectively.   
Conclusions: About 33-60% of all users discontinued their therapies. 
Beneficiaries receiving subsidies had low OOP costs, averaging between $0.03 and $6.34 
per day. Beneficiaries on the more expensive drugs and not having subsidies had high 
OOP costs, averaging between $15.66 and 36.84 per day. Higher OOP costs were 
associated with an increased likelihood of discontinuation or delay.
CHAPTER 1 
 INTRODUCTION 
In 2011, cancer was the second leading cause of death in the United States. Out 
of 2,512,873 total deaths in the U.S., the number of deaths from cancer was 575,313.
1
  In 
2010, the direct costs for cancer treatment were $124.57 billion in the U.S. Expenditures 
are likely to increase as new medications, such as treatments that work against targeted 
cancer cells, and other more advanced therapies reach the market.
2
 
 A substantial and increasing number of cancer patients are now being treated 
with oral cancer therapy. The total US cancer drug market was estimated to be $35 billion 
in 2011 and the growth rate was estimated to be between 15 and 16 percent.
3
  By 
comparison, in 2010, the oral cancer drug market was estimated to be between $5 billion 
and $7 billion with an annual growth rate between 20 and 30 percent.
4
  It has also been 
estimated that more than twenty-five percent of the 400 antineoplastic drugs in the 
development pipelines are oral agents.
5
  Currently, twenty-four oral cancer agents are in 
phase 3 clinical trials.
6
 
Nonadherence with drug treatment is a major problem for patients with chronic 
diseases. For example, nonadherence rates were between 21%-35% for diabetes 
patients,
7-9
 21%-32% for post-myocardial infarction patients,
10,11
 13%-41% for epileptic 
patients,
12-15
 and 50%-61% for hypertensive patients.
16-18
  Nonadherence has been linked 
to both negative health outcomes and increased healthcare expenditures.
15,19-21
  For 
example, nonadherence to chronic drug therapy has been associated with increases in 
relapse risk in acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia 
(CML), and schizophrenia,
22,23
 increased emergency department (ED) visits in epilepsy, 
2 
 
hypertension, chronic heart disease, diabetes, and hypercholesterolemia,
14,15,24
 increased 
hospitalizations in epilepsy, heart failure, myocardial infarction, and diabetes,
9,14,15,25,26
  
increased mortality in heart failure, myocardial infarction, and diabetes,
9,25,26
 reduced 
responses to treatment in CML,
27,28
 and lower event free survival in CML and heart 
failure.
29,30
 Adherence is likely to be a major problem for patients on oral cancer drugs 
because of the high cost of oral chemotherapy. Most oral cancer drugs are branded and 
expensive medications that do not have generics available. Moreover, high cost of 
prescriptions is a major cause of nonadherence to medications.
31-33
 
Older patients are both more likely to have cancer and to be at risk for 
adherence problems with oral cancer drugs.
34-38
  The number of cancer survivors in the 
US increased from 9.8 million in 2001 to 13.7 million in 2012.
39,40
  Over half of that 
population, (i.e. approximately 9.72 million) was elderly (aged 60 years old or older).
40
 
The National Cancer Institute (NCI) reported that the 2004-2008 incidence rates for 
cancer in individuals aged 65 years and older were 2,127.8 cases per 100,000 population 
compared with 223.8 cases per 100,000 population for those aged under 65 (age adjusted 
to 2000 US standard population).
41
  The restrictions of the Part D drug program, 
including the coverage gap and high cost-sharing, and the high cost of oral chemotherapy 
result in high patient out-of-pocket (OOP) spending for cancer drugs.
42
  For example, a 
beneficiary enrolled in Universal American’s Community CCRx Basic plan filling 
lenalidomide (Revlimid
®
) paid $4,263 OOP for the first month of treatment in 2009. This 
included a $295 deductible and a 55 percent cost-sharing of the drug price $7,214. OOP 
spending of this magnitude would pose a substantial financial burden and could result in 
patients stopping their treatment.  
3 
 
In addition, most elderly Medicare beneficiaries are retirees and have limited 
incomes; half have incomes less than 200% of the Federal Poverty Level (FPL).
43,44
  A 
recent study showed that Part D enrollees who did not have previous drug insurance 
coverage were more likely to have low income, with personal annual incomes of less than 
$25,000, compared with elderly who were not Part D enrollees.
45
  As a result, high OOP 
spending could have a substantial impact on elderly patients’ ability to obtain and adhere 
to drug therapy. 
The Medicare Part D prescription drug benefit became effective on January 1, 
2006. The purpose of this program was to improve prescription drug coverage and 
increase access to medications by offering affordable prescription drugs to Medicare 
beneficiaries. Medicare Part D prescription drug plans use cost-sharing strategies to 
contain unnecessary and costly use of brand-name prescription drugs. Enrollees are 
required to pay initial deductibles and cost-sharing for their medications. The Part D 
benefit is offered to consumers through private health plans. Two types of drug benefit 
plans are available to beneficiaries: standalone prescription drug plans (PDPs) and 
Medicare Advantage Prescription Drug (MA-PD) plans. Both PDPs and MA-PD plans 
offer prescription coverage, but MA-PD plans additionally offer medical coverage. The 
majority of Medicare beneficiaries have enrolled in PDPs since Part D was     
implemented. 
46,47
 
4 
 
The Standard Part D benefit includes four benefit phases: deductible, pre-initial coverage 
limit (pre-ICL), ICL or coverage gap (also known as the doughnut hole), and catastrophic 
coverage. Beneficiaries are required to pay the full amount of their medication costs 
during the ICL or coverage gap. The standard initial deductible, ICL, OOP threshold, and 
catastrophic coverage levels vary each year based on drug prices.
48
 Part D benefit plans 
may also offer alternative benefit designs, such as using formulary tiers, decreasing 
deductibles, and offering coverage during the coverage gap. Part D monthly premiums 
are determined by the plans;
2 
additionally, they are based on beneficiaries’ incomes. 
Enrollees whose gross annual incomes exceed set amounts are required to pay higher 
monthly premiums.
49
 
In 2008, the standard benefit in PDPs included an initial $275 deductible. 
Beneficiaries paid 25% coinsurance for total medication costs between $276-2,510; 
beneficiaries were required to pay 100% of their medication costs after exceeding the 
initial coverage limit of $2,510; and they paid a 5% coinsurance after annual prescription 
costs exceeded $5,726.25 (catastrophic coverage). Before enrollees exited the coverage 
gap ($5,726.25), they had to pay total OOP drug costs of $4,050 (True OOP or OOP 
threshold).
5  
The maximum OOP spending has increased every year from $3,600 in 2006 
to $3,850 in 2007 and $4,050 in 2008.
48
 
According to 2008 national Medicare Part D plan statistics, there were a total of 
1,824 Part D plans, of which approximately 71% offered no coverage during the gap. The 
lowest monthly premium was available at $9.80 with no gap coverage and the highest 
was $107.50 offering coverage for preferred generics during the gap.
50
  At that time, no 
Part D plans offered full coverage for all brands and generics in the coverage gap.
51
 
5 
 
Most plans use tiered cost-sharing; expensive drugs are frequently included on     
a specialty tier. Antineoplastics, immunologics, antivirals, and antibacterials account for 
more than half of specialty drugs. Since 2006, specialty tiers have been used increasingly 
by plans: in PDPs they increased from 63 to 76 percent and in MA-PDs from 67 to 90 
percents from 2006 to 2008.
52
 
Tier structures can differ among plans. Most PDP plans provide tiered formularies 
in which beneficiaries pay larger amounts for non-preferred drugs. In general, plans are 
required to provide at least two drugs in each therapeutic class. However, antineoplastic 
medications are one of six classes of drugs for which plans are required to cover “all”     
or “substantially all” medications in the class on their formularies.47,53  The Center for 
Medicare and Medicaid Services (CMS) has set the maximum cost-sharing for specialty 
drugs at 25 percent, but plans are allowed the flexibility to charge a higher cost-sharing   
if it is combined with lower deductibles. Half of plans charge their members up to 33 
percent coinsurance for specialty tier medication.
52 
 
 
 
 
 
 
 
6 
 
The Medicare Benefit and Cancer Medications 
Injectable oncolytic products and some oral chemotherapy are covered by 
Medicare Part B and provided in physician offices. Oral dosage forms are covered under 
Part B if they are available in injectable forms or as prodrugs. The eight oral cancer drugs 
that are currently available under Part B include capecitabine (Xeloda
®
), methotrexate, 
cyclophosphamide (Cytoxan
®
), temozolomide (Temodar
®
), busulfan (Myleran
®
), 
etoposide (VePesid
®
), melphalan (Alkeran
®
), topotecan hydrochloride (Hycamtin
®
). 
Otherwise, self-administered and oral cancer drugs are covered under Medicare Part D.
54
 
Oral cancer medications may also be covered by Part D if they have indications for 
conditions other than cancer in at least one of the three mandated compendia. These 
compendia include American Hospital Formulary Service Drug Information, US 
Pharmacopeia-Drug Information, and DRUGDEX Information System.
55
  Part D drug 
plans cannot include the eight Part B covered oral cancer drugs (previously mentioned) 
on their formularies if the indications are solely for cancer treatment. However, if those 
drugs are used for other indications, they can be included under a prior authorization 
program.
53,56
 
Medicare excluded reimbursement for self-administered cancer medications 
when it was implemented in 1965. In 1993, Congress authorized coverage for seven oral 
cancer drugs with injectable equivalents.
57
  In 2005, Congress authorized and funded a 
demonstration project for coverage for oral and self-administered drugs. The 
demonstration project included thirteen cancer drugs in 50,000 eligible patients. 
Coverage of oral medications, including cancer drugs, was expanded to cover all 
Medicare enrollees in 2006.
58 
7 
 
Typically, the differences between oral and injectable cancer agents are the 
following: 1) oral cancer drugs are covered under the pharmacy benefit but injectable 
agents are covered by the medical benefit; 2) oral agents are dispensed by a pharmacy 
whereas injectable products are administered in a physician’s office;59 and 3) oral cancer 
agents are more expensive than injectable medications. As a result, patients have higher 
cost-sharing for oral cancer drugs.
5,59
  Also, Part B enrollees pay a lower cost-sharing 
percentage for their therapy than Part D beneficiaries. For example, Part B enrollees paid 
20 percent cost-sharing in 2008,
2
  but Part D patients paid, on average, a $250 deductible, 
25% coinsurance during the pre-ICL phase, and the full amount of medication costs when 
they entered the coverage gap.
46
  Medicare beneficiaries who enroll in Part D prescription 
drug plans also paid higher cost-sharing than those who have private insurance 
coverage.
60
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Oral Cancer Medications 
Patients prefer using oral chemotherapy rather than parenteral drugs. The main 
reasons for the preference for oral therapy include convenience, avoidance of intravenous 
access issues, flexibility for timing and location of administration, and increased quality 
of life.
61-64
  Particular concerns when prescribing oral agents are compliance and that 
physicians are unable to monitor side effects of oral cancer agents.
5,47,65,66
  Patients have 
the full responsibility to manage their medications. As a result, patients may decide, 
without medical advice, to reduce the dose or stop taking oral agents. Moreover, higher 
cost-sharing for oral cancer drugs may increase non-compliance.
67,68
 
In addition, the lack of availability of less expensive generics leads to higher 
costs for oral cancer drugs. More than 75 percent of Food and Drug Administration 
(FDA)-approved oral cancer drugs were brand name drugs.
69 
 High cost of oral cancer 
agents is a significant reason that patients delay or skip their treatment.
70 
 Consequently, 
providers must consider cost when prescribing an oral cancer agent.
71-73
 
In prescribing oral cancer medication, health providers shift the majority of 
responsibility directly to patients to manage their regimens. Therefore, adequate patient 
education is required to ensure that patients receive oral chemotherapy safely and 
effectively.
18   
Oral chemotherapy prescriptions can be filled in any pharmacies, including 
“community pharmacies, mail-order pharmacies, specialty pharmacies, hospital 
pharmacies, through the physician’s office as part of Competitive Acquisition Program 
(CAP), or through an office based pharmacy.”5  A recent study reported a number of 
community pharmacists who were unfamiliar with oral chemotherapy.
74
  As a result, 
patients who filled their prescriptions for oral chemotherapy at a community pharmacy 
9 
 
may have received inadequate information or misunderstood the instructions for taking 
the oral agent.
5
 
Increases in the use of oral oncolytic drugs present challenges to patients.
5
      
The cost of oral agents averages approximately $43,000 per patient per year.
6
  As a result, 
Medicare beneficiaries could enter the coverage gap quickly. However, some patients 
who have financial difficulty could apply for pharmaceutical assistance programs offered 
by the pharmaceutical companies.
2,6,75
  Medicare enrollees with low income may be 
eligible for the low income subsidy (LIS) program, in which they pay lower cost-sharing 
for their prescriptions. For example, regular Part D patients paid a $275 deductible and 
25% of prescription costs up to the coverage gap, then the full cost of their medication. 
LIS patients with full subsidies paid $2.25 (Generic) and $5.60 (Brand) copays if they 
had resources less than $6,120 or 15% coinsurance if their resources were between 
$6,120-$20,210. Full subsidy patients with resources below $6,120 were not required to 
pay copayments in the catastrophic coverage phase; otherwise they paid copayments of 
$2.25 (Generic) and $5.60 (Brand).
3   
Resources are determined from assets that can be 
converted to cash within 20 days, including stocks, bonds, and bank accounts. However, 
home, car and life insurance policies are not included in the resource limit.
76
 
The reasons that enrollees could stop filling prescriptions due to cost may come 
from lack of awareness of cost-sharing, low income, or financial burden. A recent study 
showed that a majority of beneficiaries were not aware of the coverage gap in their 
benefit plans or of the amount of copayments that they were required to pay. Only one-
fifth of enrollees paying copayments could identify the amount of generic and brand 
name co-pays.
77
 The awareness of the coverage gap was highest among enrollees who 
10 
 
reached the gap. Greater than one third of beneficiaries reported cost-related behaviors 
such as switching to generics or reducing adherence. Moreover, enrollees with higher 
annual drug costs had higher magnitudes of cost-related responses; more than half of 
beneficiaries (57%) with $3,500 and greater of annual drug costs reported cost related 
behaviors.
77
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
Part D Oral Cancer Drugs in the Current Study 
This study examined the top five oral cancer drugs of 2008 that were covered   
by Part D. In order by sales, they are: imatinib (Gleevec
®
), anastrozole (Arimidex
®
), 
letrozole (Femara
®
), erlotinib (Tarceva
®
), and thalidomide (Thalomid
®
).
78
 
The non-steroidal aromatase inhibitors, anastrozole and letrozole, are used in 
early and advanced breast cancer in postmenopausal women. National Comprehensive 
Cancer Network (NCCN) guidelines recommend using the non-steroidal aromatase 
inhibitors as an adjuvant endocrine therapy for five years of treatment in postmenopausal 
women or in premenopausal women as sequential therapy following 2-3 years of 
tamoxifen. Because there is biological equivalence between these agents;
79
 if patients are 
unable to tolerate the first aromatase inhibitor, they could switch to use the second 
medication.
80
 
Imatinib and erlotinib are members of a class of drugs known as tyrosine kinase 
inhibitors (TKIs). Imatinib was first approved for use in chronic myeloid leukemia 
(CML) patients in 2001. Imatinib is a long-term treatment that depends on hematologic, 
cytogenetic, and molecular responses.
81
  Patients with CML require daily treatment 
during the chronic phase of the disease. The initial treatment is 400 mg once daily for at 
least 3 months with follow-up evaluation required. If there are complete cytogenetic, 
hematologic and molecular responses, the same doses can be continued up to 12 months 
of treatment with follow-up evaluation every 3 months; however, the doses can be 
increased to 800 mg if there are minor cytogenetic responses.
81
  Treatment with imatinib 
12 
 
is continued until disease progression or patient intolerance toxicities. Therefore, 
theoretically treatment with imatinib can continue for many years.  
In patients who are resistant or intolerant to imatinib, the newer generation of 
TKI medications, including dasatinib and nilotinib has been approved as a second-line 
therapy for CML in 2006 and 2007, respectively.
82
 
Erlotinib has been approved for second line monotherapy or maintenance 
treatment for advanced or metastatic non-small cell lung cancer (NSCLC) since 2004.
83
 
A dosage of 150 mg once daily is suggested for use in non-small cell lung cancer 
treatment. The NCCN guidelines recommend using erlotinib as a first line therapy only 
for patients with epidermal growth factor receptor (EGFR) mutation, but there is no 
recommendation for the duration of treatment or dosage.
84
  It is suggested that erlotinib 
use can be continued for patients with NSCLC until the disease progresses or there is 
unacceptable toxicity. Moreover, docetaxel or pemetrexed can be used as a second-line 
monotherapy for NSCLC.
84
  
In 2006, the FDA approved dose of thalidomide is 200 mg in combination with 
dexamethasone for multiple myeloma treatment.
85
  Subsequently, NCCN guidelines 
recommend using thalidomide in combination with bortezomib and dexamethasone as 
one of the preferred regimens of primary therapy for patients who anticipated undergoing 
stem cell transplant. Thalidomide is recommended with melphalan and prednisolone in 
patients not eligible for stem cell transplant. Additionally, thalidomide in combination 
with dexamethasone has been shown effective as maintenance treatment for multiple 
myeloma.
86
  There is no recommendation for the duration of treatment with thalidomide 
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for multiple myeloma. However, the median survival in thalidomide users was 65.5 
months.
87
 
Conceptual Framework 
This study has been derived from the conceptual framework of cost-related 
nonadherence (CRN).
88
  The conceptual framework for medication discontinuation can 
be adapted from the CRN model offered by Piette et al. The framework shown in Figure 
1 was used to estimate the relationship between total OOP spending and medication 
discontinuation. The relationship between OOP costs of prescription drugs and adherence 
is complex; nonadherence due to costs of medications cannot be estimated solely based 
on patients’ financial burden. Piette included financial and non-financial factors 
associated with nonadherence into the model. These factors were financial characteristics, 
regimen complexity, and characteristics of disease, patients and medication. Financial 
characteristics involve prescription costs, OOP costs, total household income, and 
prescription drug coverage. Regimen complexity is defined as numbers of prescriptions 
and frequency of refills. Moreover, clinician and health system factors influence the 
effects of medication costs on patients’ adherence. Cost pressures and regimen 
complexity are possibly minimized by those factors.
88
 
This study evaluated the influence of regimen complexity, financial factors, 
patient characteristics, disease characteristics, and prescription characteristics on 
medication discontinuation. Clinician and health system factors were excluded because 
no data are available in the Medicare Part D data related to these factors.   
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The model indicates that pressures from financial factors are one of the reasons 
leading patients to not adhere to their medication. Financial factors include income, 
prescription coverage, OOP prescription costs, and other health costs. It was 
hypothesized that patients with high OOP spending were more likely to discontinue their 
medications.
  
This relationship may be stronger in cancer patients because of the high cost 
of these drugs. On the other hand, the relationship might be weaker because cancer drugs 
are perceived to be life-saving treatments.
88
 
There is a positive correlation between income and prescription use.
89
  It was 
hypothesized that patients with low income are less likely to adhere to their 
medications.
90
 
Regimen complexity includes numbers of prescriptions and the frequency of 
refills that patients have had. Both of these factors affect medication adherence. It was 
hypothesized that patients with high numbers of prescriptions and refills would be more 
likely to have medication nonadherence.
91,92 
The Piette et al model includes socio-cultural influences, perceived benefits of 
treatment, mental status, self-efficacy, and health literacy as patient characteristics that 
influence nonadherence due to prescription cost.
88
  Because of the availability of 
information in Part D claims data, only variables regarding socio-cultural influences and 
mental status were included in our analysis. Differences in socio-demographics, including 
race, age, and gender, may have an impact on adherence to medication. For instance, 
non-white patients were more likely to forgo medication use due to cost and used less 
medication than white individuals.
93
 Patients with depression had more risk of underuse 
of medication due to cost than non-depressed patients.
88 
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Prescription characteristics include adverse effects, dosing complexity and 
perceived need. We were unable to incorporate prescription characteristics into the 
analysis. Disease characteristics have some effects on current health related quality of life 
(HRQL) and life expectancy. Patients’ comorbidities will be used as the indicators for 
this effect. Comorbidities will be determined from the variables indicating the chronic 
conditions from which patients suffered during the study period. These include acute 
myocardial infarction, stroke, Alzheimer’s disease, chronic kidney, chronic obstructive 
pulmonary disease, heart failure, stroke, glaucoma, rheumatoid arthritis, osteoporosis, 
and diabetes.     
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Figure 1 Conceptual framework for the factors influencing rates of cost-related medication underuse.
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CHAPTER 2 
LITERATURE REVIEW 
Cost and use of oral cancer medications 
A recent study conducted by Raborn et al. identified the total OOP payments by 
payer type for 21 oral chemotherapies in managed care plans.
94
 
They used patient-level medical and pharmacy claims data provided by the IMS 
LifeLink: Health Plan Claims Database. The inpatient and outpatient diagnoses 
(International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM)) files and Current Procedural Terminology (CPT) Fourth Edition Coding System 
formats were used to identify cancer type. Demographic variables, payer type, provider 
specialty, charges, allowed and paid amounts, and plan enrollments were included. Adult 
patients aged 18 years and older who had at least one claim for one of the study drugs 
were included. The 21 drugs in the study included: altretamine, bexarotene, capecitabine, 
cyclophosphamide, dasatinib, erlotinib, etoposide, everolimus, gefitinib, imatinib, 
isotretinoin, lapatinib, lenalidomide, nilotinib, sorafenib, sunitinib, temozolomide, 
thalidomide, topotecan, tretinoin, and vorinostat. The index date for each patient was the 
date of his/her first prescription filled. Each patient was required to have continuous 
health plan enrollment for 6 months before and after the index date. Patients who were 65 
years or older were included if they were in a “Medicare Risk (private Medicare) plan.” 
Medicare Part D data were not available in their database. The primary outcome was the 
OOP costs for oral cancer drugs in 2009. They calculated OOP costs as the allowed 
amount minus the paid amount. Per claim OOP costs were identified in aggregate for 
each medication. OOP payments were classified by payer type, including commercial, 
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Medicaid, Medicare Risk, self-insured, and unknown. Patient demographics, including 
age, gender, geographic region, health plan and payer types, and clinical characteristics, 
including cancer type, were evaluated. 
Descriptive statistics: means, median, and standard deviation were reported. 
Differences in OOP payments were measured using analysis of variance. A total sample 
of 6,094 patients was included. The mean age was 53 years and 54% of the total sample 
were women. The lowest mean OOP cost per claim was $15 for cyclophosphamide and 
the highest was at $527 for dasatinib. Mean OOP costs were $225 for erlotinib, $154 for 
imatinib, and $193 for thalidomide. They classified study drugs in two groups: 
medications with available generics and without available generics. The mean OOP cost 
was lower for drugs with available generic substitutes with a mean cost of $31 versus 
$171 for drugs without available generic drugs. Overall, 66% of the patients paid less 
than $50 per claim, for 21% OOP costs exceeded $100. Patients with Medicare Risk 
(private Medicare) plans paid significantly higher OOP payment than patients with other 
payers (p<0.001).
94
 
Goldman et al. studied the utilization of specialty cancer drugs by evaluating the 
relationship of patients’ incomes and their OOP payments to drug use.95  This study used 
regression to estimate the association between cost-sharing and the probability of 
initiating therapy and the number of claims. Administrative claims data were selected 
from the health plans offered by 15 employers, from claims collected between 1997 and 
2005.  Data were collected from more than 50 health plans. The five oncolytic agents 
studied included both oral and injectable products. The oral agents were erlotinib 
(Tarceva
®
) and imatinib mesylate (Gleevec
®
), and the injectible products were 
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bevacizumab (Avastin
®
), trastuzumab (Herceptin
®
), and rituximab (Rituxan
®
). They 
studied the elasticity of demand in rituximab and the remaining drugs in two groups: all 
eligible patients and metastatic cancer patients. In the all eligible patient group, they 
found that the estimated elasticity of demand for rituximab was -0.258 (p<.05), and was -
0.189 for the other drugs. The elasticity of demand was less in metastatic patients: -
0.0367 (p<.01) for rituximab and -0.108 (p<.05) for non-rituximab drugs. A twenty-five 
percent lower OOP spending was associated with a 6.4 percent higher initiation of 
rituximab treatment in the all eligible patients group. In the remaining drugs, twenty-five 
percent lower OOP was associated with 4.7 percent higher initiation.
95
 
A study done in 2006 by Bowman et al. looked at variation in the coverage and 
cost-sharing for cancer drugs covered by Medicare Part D.
96
  They focused on cost-
sharing of beneficiaries and comparison of formulary coverage across the plans. 
However, the use of cancer drugs and the impact of coverage were not studied. The “1 
February 2006 extract of the CMS Prescription Drug Plan Formulary and Pharmacy 
Network Files” was used. Cancer drugs were stratified by type of plan: local MA-PD, 
regional MA-PD, and PDP. They examined average tier position, median coinsurance or 
copayments in the initial coverage phase, variation in coverage across benefit plans, and 
frequencies with which the cancer drugs were covered in the formularies. The percentage 
of generic cancer drugs that was covered was higher than that of brand name drugs. 
Regional MA-PD plans covered (p<0.01) significantly more of the cancer drugs, more 
frequently covered both generic and brand-name drugs, and less frequently used prior 
authorization than those of PDPs and local MA-PD plans. Fifteen out of twenty drugs 
most frequently covered on the formularies were brand-name drugs. Each of those twenty 
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drugs was listed on the formularies of all PDPs and more than 99 percent of MA-PD 
plans.  
Most Part D plans have a tiered-cost-sharing structure in their formularies. 
Brand-name medications are mostly covered on higher tiers with higher coinsurance or 
copayment while generic drugs are on lower tiers with lower cost sharing. For example a 
typical tier structure might include generic drugs on the first tier, preferred brand-name 
drugs on the second tier, non-preferred brand-name drugs on the third tier, and specialty 
drugs on a fourth tier.
97
   
The average cost-sharing tier was 2.1-3.1 for brand name versus 1.0-1.2 for 
generics. Most Part D benefit plans use a fixed copayment rather than coinsurance. 
However, most PDPs used coinsurance for imatinib and erlotinib. The median 
copayments for a thirty-day supply were $5-40 for PDPs versus $5-35 for MA-PD plans. 
The median coinsurance rate for both PDPs and MA-PD plans was 25 percent.
96
 
Streeter et al. examined the abandonment rate of oral cancer medications and 
the factors associated with abandonment.
60
  Administrative claims data from the Wolters 
Kluwer Dynamics Claim Lifecycle Database, a nationally representative pharmacy 
utilization data source, were used. The sample included data for 10,508 patients who met 
the inclusion criteria between January 1, 2007 and June 30, 2009. The inclusion criteria 
were as follows: 1) patients who were enrolled in non-Medicare commercial plans or 
Medicare plans, 2) patients who had at least one claim for any medication at least 120 
days before the first oral cancer drug claim and at least 90 days after the first oral cancer 
agent claim, 3) patients who had a claim for at least one of these eight agents: 
capecitabine, imatinib, sorafenib, lenalidomide, sunitinib, erlotinib, temozolomide, and 
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lapatinib. Abandonment status was determined within 90 days after a claim for an oral 
oncolytic agent was initiated. An abandoned claim was defined as a prescription which 
had been prescribed, submitted by the pharmacy for third party reimbursement then 
reversed after adjudication, and which had not been followed up with a subsequent drug 
within 90 days. Ten percent of the total sample abandoned their oral cancer medication. 
The factors that were significantly associated with the abandonment rate were number of 
claims and pharmacy benefit design. Patients with cost-sharing of more than $500 
(OR=4.46, P<0.001) and patients with five or more claims (OR=1.50, p<0.001) were 
more likely to abandon oral cancer drugs than those with cost-sharing less than $100 and 
those with no claims, respectively. In addition, patients with Medicare coverage had 
significantly higher OOP spending than those with commercial coverage (p<0.001) and 
rates of abandonment were higher after the second quarter of the year (between April and 
December) than in the first quarter (p<0.05).
60    
Recently, Short et al. estimated medical expenditures for adult cancer survivors 
who were less than 65 years old.
98
 A cancer survivor is defined by the National Cancer 
Institute (NCI) as a living individual diagnosed with cancer.
99
  Data from the Household 
Component of the Medical Expenditure Panel Survey (MEPS-HC) were linked with data 
from the National Health Interview Survey (NHIS) data to calculate the estimated 
expenditures for cancer survivors. Pooled data from 2001 to 2007 were included and 
weighted to be representative of the U.S. adult population. The total sample of 
individuals aged 25-64 years was categorized into three groups: 1) newly diagnosed 
survivors (n=361), 2) previously diagnosed survivors (n=2,119), and 3) not a survivor 
(i.e., patients with no history of cancer) (n=47,690). Propensity score matching 
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techniques were used to estimate the effect of cancer on the expenditures of cancer 
population. Probit models were developed to estimate the effects of cancer on the 
distribution of total and OOP expenditures. Mean annual expenditure for all services was 
$16,910 ± $3,911 for newly diagnosed survivors, $7,992 ±$972 for previously diagnosed 
survivors, and $3,303 ± $103 for individuals without a history of cancer. The mean of 
prescription expenditures was $2,347 for newly diagnosed survivors, $1,691 for 
previously diagnosed survivors, and $754 for adults with no history of cancer. The mean 
of OOP expenditures for prescriptions was $808 for newly diagnosed survivors, $607 for 
previously diagnosed survivors, and $265 for adults with no history of cancer. They 
estimated that cancer added $832 ± $286 to the average annual prescription expenditure 
for female cancer survivors and $1,219 ± $637 for male survivors. It was estimated that 
approximately twenty percent of previously diagnosed survivors aged 40-64 years old 
paid more than $2,000 OOP. This study showed that cancer is significantly associated 
with higher total medical expenditures and higher OOP spending, especially for those 
who were newly diagnosed.
98
 
Cost-related nonadherence 
Most cost-related nonadherence (CRN) studies have been conducted using self-
reported survey data. There is no gold standard definition of CRN. Previous studies have 
defined CRN as the self-reported behaviors relating to cost of prescriptions. According to 
this definition, patients who reported any of the following behaviors were labeled as 
experiencing CRN: 1) delayed or stopped filling or refilling of a prescription because it 
was expensive, 2) skipped doses to make the prescription last longer, and 3) used less 
medication than prescribed to make it last longer.
100-104
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Cost-related nonadherence in cancer patients 
We found only one study examining CRN in Medicare cancer patients.  
Nekhlyudov et al.
 
conducted a CRN study in elderly Medicare beneficiaries.
100
  CRN was 
compared between the Medicare enrollees with or without cancer using 2005 Medicare 
Current Beneficiary Survey (MCBS) data. They categorized the sample into two groups: 
enrollees with and without cancer based on the ICD-9 claim codes for any cancer. The 
outcomes of interest included the self-reported CRN, spending less on basic needs to 
afford medicine, and cost reduction strategies. The cost reduction strategies used to offset 
medication costs included: using generic substitution, requesting free samples, using 
mail-order or internet, obtaining medication from outside the US, and comparing prices 
before filling prescriptions. Descriptive statistics and logistic regression were used to 
measure CRN and cost-reduction strategies. Covariates included demographic and socio-
economic variables, self-reported health status, type of drug coverage, number of years 
participating in MCBS, and the year of survey. Of 9,818 non-institutionalized elderly 
Medicare enrollees, 14% had at least one cancer claim. Cancer survivors were more 
likely to be male, non-Hispanic, older, more educated, and have multiple comorbidities, 
poor health status, and employer based insurance coverage. Of the total cancer survivors, 
10.3% reported CRN and 6.3% reported forgoing basic needs. Cancer survivors who 
reported CRN were more likely to be African American, have income <$25,000, and do 
not have drug insurance coverage, compared to cancer survivors without CRN. 
Moreover, cancer survivors who reported spending less on basic needs were more likely 
to be African American, female, have incomes less than $25,000, and not have a high 
school education than those who did not report spending less on basic needs. For cost-
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reduction strategies, approximately half of all enrollees reported that they used generic 
substitution or requested free samples. Cancer survivors were more likely to use mail-
order or obtain their medications from internet compared to non-cancer patients.
100
  
Cost-related nonadherence in Medicare Part D program 
A recent study was conducted by Williams et al. using data from the Translating 
Research into Action for Diabetes (TRIAD) survey of patients in 8 western states.
101
  The 
TRIAD survey randomly selected Medicare beneficiaries who 1) were 65 years or older 
by January 1, 2005, 2) had total prescription costs that exceeded $2,250 by October 1, 
2006, and 3) were continuously enrolled in an MAPD plan between January 1, 2005 and 
December 31, 2006. Beneficiaries who had full prescription coverage in the coverage gap 
and LIS beneficiaries were excluded because they did not have a coverage gap. 
Telephone interviews were conducted among elderly Medicare Part D 
beneficiaries with diabetes who entered the coverage gap in 2006. CRN was identified 
based on pharmacy claims data records and telephone interviews. The interviewers 
identified nonadherence to medications that were not recorded in pharmacy claims by 
asking each participant to bring their medications to the phone during the interview. A 
total of 1,264 participants were asked whether they had any CRN to any medication they 
took during 2006. The specific drugs were identified if participants took less because of 
cost. Multivariate logistic regression analyses were used to examine CRN controlling for 
other variables, including comorbidity count, OOP costs in the first quarter of 2006, sex, 
race, gender, educational attainment, annual income, plan type, and medication coverage 
during the coverage gap. The type of medications was created as indicator variables, 
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including: diabetes, hypertension, cholesterol-lowering, symptom relief, and others. 
These indicators were used as the main predictors in the analyses. The authors found a 
16% prevalence of CRN occurred with any medication. CRN was higher with 
cholesterol-lowering medication (Relative Risk (RR), 1.54; 95% CI, 1.01-2.32), or an 
annual income less than $25,000 (RR, 3.05; 95% CI, 1.99-4.65). As age increased, rates 
of CRN decreased.
101
  
Frankenfield et al. conducted a CRN study among Medicare Part D 
beneficiaries with end-stage renal disease (ESRD).
102
  The 2007 Medicare Consumer 
Assessment of Health Providers and Systems Survey (CAHPS) was used to obtain CRN 
information. This is a national survey of a randomly selected sample of community 
dwelling Medicare beneficiaries. CRN was evaluated based on whether participants 
delayed filling a prescription because of cost in the last six months. Covariates included 
socio-demographics, health status measures, selected health behaviors, accessibility to the 
healthcare system and providers, chronic condition risk scores, and whether they were a 
new Medicare enrollee. Multivariate logistic regression was used to estimate the CRN 
risk, controlling for demographic characteristics, socio-economic status, chronic 
conditions, and health behaviors. Sixteen percent of the total sample reported CRN. 
Furthermore, for the total Medicare beneficiary sample, CRN was found to be 
significantly associated with the following variables: chronic conditions, including 
ESRD, diabetes, chronic obstructive pulmonary disease (COPD), congestive heart failure 
(CHF), and mental disorders; race, including American Indian, black, or Hispanic; low 
educational attainment (less than high school), lower socio-economic status (SES) score, 
female, younger than 65 years old,  smoking, poor self-reported health status, lower 
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personal-physician rating, and filling six or more prescriptions in the past six months. 
Respondents with ESRD were more likely to report CRN than those without ESRD. Of 
the 1,329 respondents with ESRD, 31% reported CRN. Respondents with ESRD were 
23% more likely to report CRN than those without ESRD. The odds ratio for CRN in 
respondents with ESRD was 2.34 (95% CI, 2.0-2.75) for the unadjusted model and 1.23 
(95% CI, 1.07-1.41) for the adjusted model. Respondents who identified as Black and 
those receiving LIS were significantly more likely to report CRN.
102
 
Kennedy et al. conducted a CRN study in Medicare Part D beneficiaries. They 
examined how CRN changed with Part D implementation and whether the extent of CRN 
changed from 2005 to 2006 among three groups.
103
  The three groups included newly 
insured beneficiaries, continuously insured beneficiaries and continuously uninsured 
beneficiaries. MCBS access to care files were used to compare rates of CRN and changes 
in CRN. Multinomial logistic regression was used to estimate changes in CRN by 
insurance status controlling for other covariates. They categorized CRN changes into 4 
levels, including: 1) Resolved CRN (CRN was reported in 2005 but not in 2006), 2) 
Unresolved CRN (CRN was reported in 2005 and 2006), 3) New CRN (CRN was 
reported only in 2006), and 4) No CRN (CRN was not reported in either 2005 or 2006). 
After the introduction of Medicare Part D, CRN rates decreased from 15.4% in 
2005 to 11.3% in 2006. Newly insured beneficiaries were more likely to have resolved 
CRN (OR=1.6; 95% CI 1.3-2.2), and unresolved CRN (OR=2.1; 95% CI, 1.5-2.9) than 
continuously insured beneficiaries. Continuously uninsured beneficiaries were more 
likely to report unresolved CRN (OR=1.8; 95% CI, 1.3-2.4) than continuously insured 
enrollees. Moreover, disabled Medicare beneficiaries who were younger than 65 years 
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old were more likely to report all CRNs (resolved, unresolved, and new CRN) than 
elderly beneficiaries. Beneficiaries with fair or poor health were more likely to report 
resolved (OR=1.3, 95% CI, 1.1-1.6), unresolved (OR=1.7; 95%CI, 1.3-22) and new CRN 
(OR=1.4; 95% CI, 1.1-1.9). Beneficiaries with multiple chronic diseases or depression 
were more likely to report CRN.
103
   
Madden et al.estimated the changes in CRN following Part D implementation 
using longitudinal MCBS data from 2004 to 2006.
104
  Data from community dwelling 
respondents from the MCBS access to care files were included. The CRN measure was 
obtained from the three questions in the MCBS data as mentioned previously. In addition, 
they measured whether beneficiaries spent less on food, heat, or other basic needs for 
medicine. They used logistic regression models to estimate changes in CRN and whether 
beneficiaries spent less on basic needs over time. The models were weighted and 
controlled for the interview sequence, demographic characteristics, and health status.  
Changes in CRN and spending less on basic needs declined significantly after Part D 
implementation. The adjusted odds ratio for CRN was 0.85 (95%CI, 0.74-0.98) and the 
OR for spending less on basic needs was 0.59 (95%CI, 0.48-0.72). The decline in CRN 
was significantly associated with elderly status, good or excellent self-reported health 
status, fewer comorbidities (2-3 diseases), and lower income. The tendency to forgo basic 
needs significantly decreased among all subgroups except nonelderly disabled 
beneficiaries.
104
 
Duru et al. assessed the association between generic-only gap coverage and 
cost-cutting behaviors of diabetic beneficiaries who used and did not use insulin.
105
  The 
study sample was selected from the TRIAD survey including diabetic beneficiaries who 
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reached the coverage gap by October 2006. The primary predictor was no gap coverage 
or generic-only gap coverage. Multivariate logistic models were used to measure seven 
medication cost-cutting behaviors, controlling for other covariates. The cost-cutting 
behaviors included: 1) CRN, 2) forgoing necessities because of financial hardship, 3) 
generic substitution, 4) split pills according to their doctor’s advice, 5) used an over-the-
counter (OTC) substitute, 6) used a mail-order pharmacy, and 7) called a different 
pharmacy to find the lowest price. In the insulin user group, beneficiaries with generic-
only gap coverage were less likely to report CRN than beneficiaries without gap coverage 
(16% vs. 29%; p= 0.03). CRN was not different between beneficiaries with or without 
gap coverage among non-insulin users. However, non-insulin users with generic-only gap 
coverage were less likely to switch to a cheaper medicine (36% vs 46%; p=0.01) or to 
call a different pharmacy to find a lower price than those who had no gap coverage (22% 
vs 36%; p<0.001).  Medicare beneficiaries who used insulin were at high risk of reporting 
CRN.
105
 
Zivin et al. estimated changes in CRN two years before and one year after Part 
D initiation.
106
  MCBS data were used to determine the annual prevalence and changes in 
CRN among Medicare beneficiaries with and without depressive symptoms following 
Part D implementation. The following self-reports of CRN were the main outcome 
measure: 1) “skipping doses to make medication last longer, 2) taking smaller doses of a 
medicine to make medicine last longer, 3) not obtaining prescribed medicine because it 
would cost too much, 4) not filling or refilling prescription because it was too expensive, 
and 5) spent less money on food, heat, and other basic needs so that they would have 
money for medicine.” 
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In beneficiaries with depression, spending less on basic needs declined 
significantly after part D implementation (adjusted ratio of ORs, 0.72; 95%CI, 0.52-
0.99), but CRN was not significantly different after Part D implementation (adjusted ratio 
of ORs, 0.85; 95%CI, 0.65-1.12). In non-depressed beneficiaries, spending less on basic 
needs declined significantly (adjusted ratio of ORs, 0.50; 95% CI, 0.40-0.63), and CRN 
decreased significantly (adjusted ratio of ORs, 0.83; 95%CI, 0.70-0.97) after Part D 
implementation. However, the risk of CRN persisted in depressive beneficiaries.
106
 
Madden et al. analyzed CRN after Medicare Part D implementation to 
determine whether the nationwide reduction in CRN among Medicare part D 
beneficiaries remained stable in 2007.
107
  All total community-dwelling respondents with 
MCBS data between 2004 and 2007 were included and categorized into 4 subgroups: 1) 
elderly with 0-2 morbidities, 2) elderly with 3 or more morbidities, 3) non-elderly 
disabled with 0-2 morbidities, and 4) non-elderly disabled with 3 or more morbidities. 
Self-reported CRN included “skipping or taking smaller doses to make a medicine last 
longer, or not filling a prescription because it was too expensive.”104  Moreover, other 
behaviors related to cost-cutting were included, such as “spending less on food, heat, or 
other basic needs to afford medicine.”107  CRN and forgoing basic need outcomes were 
compared for 2007 vs 2006 and 2007 vs 2005. Between 2006 and 2007, the prevalence of 
CRN decreased significantly for the overall population (OR=0.71, p<0.001) and in the 
disabled with 3 or more morbidities (OR=0.74, p<0.01). Between 2005 and 2007, CRN 
and forgoing basic needs declined significantly for the overall population (OR=0.71, 
p<0.001; OR=0.66, p<0.001) and for all subgroups (ORs between 0.58 and 0.77, p<0.05). 
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This study demonstrated that reductions in CRN and forgoing basic needs were 
maintained in the year following Part D implementation.
107
 
Castaldi et al. determined the relationship between inhaler out-of pocket costs 
and CRN among elderly beneficiaries with Chronic Pulmonary Disease (CPD).
33
  The 
2006 national survey data of non-institutionalized Medicare beneficiaries provided by the 
CMS were used. The amounts that participants spent on inhalers over the previous 30 
days were determined as OOP inhaler costs. Participants were classified into 4 groups: 
“those with CPD using inhalers, those with CPD not using inhalers, those without a 
diagnosis of CPD on inhalers, and those without either CPD or inhaler use.” CRN was 
determined by these three behaviors: not filling a prescription because of cost, skipping 
doses to make a prescription last longer, or taking smaller-than prescribed doses to make 
a prescription last longer. The CRN rate in enrollees with CPD using inhalers was 31%. 
CRN was found to have a strong association with OOP inhaler costs in Medicare 
enrollees diagnosed with CPD using inhalers. This study demonstrated that Medicare 
beneficiaries with CPD and high OOP costs for inhalers were at risk of CRN.
33
 
Overall, as this review indicated, Medicare beneficiaries experienced a high risk 
of CRN. CRN rates among Medicare Part D beneficiaries ranged between 10.3% and 
31%.
33,100-102
   CRN was higher in patients with chronic diseases, including ESRD, 
diabetes, COPD, CHF, mental disease, and high cholesterol. The risk of CRN decreased 
after Medicare Part D implementation; however, it remained unchanged in some groups 
of patients, such as depressed beneficiaries or elderly beneficiaries with comorbidities. 
The significant factors associated with increased risk of CRN included age, race, gender, 
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poor health status, low income, lack of prescription coverage, comorbidities, high OOP 
costs, and not having generic gap coverage. 
Adherence to oral cancer drugs 
A number of studies have examined adherence in patients taking imatinib and 
the aromatase inhibitors (anastrozole and letrozole). 
Wu et al. examined the association between adherence with imatinib and 
healthcare costs and utilization, controlling for comorbidities and disease severity.
108
 
They used the MedstatMarketScan Commercial Claims and Encounters database, a large 
commercial claims database. The database includes enrollment history and medical and 
pharmacy claims of employees aged 18-65 years old from large employers and health 
plans. All imatinib users treated for CML between January 1 2002 and July 31, 2008 
were identified using ICD-9-CM codes. The date of the first imatinib prescription was the 
index date. Patients were included in the study if they were continuously enrolled in a 
private plan at baseline and 12 months after the index date. The baseline was defined as a 
4 month period before the index date. ICD-9-CM codes were used to identify severity of 
CML and comorbidities. Adherence was measured using the medication procession ratio 
(MPR). MPR was calculated as “the total days’ supply of imatinib possessed by the 
patient during 12 months following the first imatinib prescription divided by 365 
days.”108  Patients with an MPR equal to 85% or higher were classified as high MPR. 
Otherwise, they were categorized as low MPR. Utilization was measured as “numbers of 
inpatient visits, emergency visits, total inpatient days, days per stay, outpatient visits, 
emergency room visit, and non-imatinib and imatinib prescriptions.”108  They included 
the costs of medical claims in which CML was a primary or secondary diagnoses and 
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pharmacy claims for imatinib as CML-related costs. Generalized linear models (GLM) 
with log link and gamma distributions were conducted to examine the relationship 
between healthcare costs and adherence. Age, gender, non-adult (aged <18 years old) 
indicator, health plan type at index date, comorbidity index, year of treatment initiation, 
severity of CML, total number of concurrent medications, and total baseline costs were 
controlled in the models. A total of 592 patients was included.  
Overall, the mean MPR was 79% (95% CI, 76-81%) and 41% of the sample had 
low MPR. Patients with low MPR had higher inpatient care costs ($44,498 vs. $3,758; 
p<0.001) and higher non-imatinib medication costs ($5,652 vs. $2,743; p<0.001) than 
patients in the high MPR group. However, patients with low MPR had lower imatinib 
costs ($22,846 vs. $40,164; p<0.001). The number of inpatient visits and total inpatient 
days were greater in patients with low MPR (p<.0.001). Low MPR was significantly 
associated with increased total costs (p<0.001). After controlling for baseline costs, CML 
severity, concomitant medications and other covariates, total medical costs were 26% 
higher and total non-imatinib costs were 178% higher in low MPR patients (p<0.001).
108
 
Darkow et al. examined the association between treatment interruptions and 
nonadherence with imatinib and health care costs among managed care patients with 
CML.
19
 The retrospective study used pharmacy and medical claim data from a managed 
care provider for the period between January 1, 2001 and March 31, 2005. Inclusion 
criteria were, 1) Patients aged 18 years and older with one prescription filled for imatinib 
from June 1, 2001 to March 31, 2004, 2) continuously enrolled in the plan 3 months 
before the index date and 12 month following the index date. The index date was the date 
of the first imatinib fill during the study period. The baseline period was assigned as 3 
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months prior to the index date. Patients were stratified into usual, moderate or high 
cancer complexity categories. Treatment interruption was defined as “failure to refill 
imatinib within 30 days from the end of supply of the prior prescription.”19 
MPR was calculated and stratified to low MPR (<50%), intermediate MPR 
(between 50 and 90%), high MPR (between 90-95%), and very high MPR (greater than 
95%). Total healthcare costs (medical services and prescription costs), imatinib costs, and 
medical costs were examined.   
Mean MPR in the first year was 77.7% (SD 27.5%).  Forty-five percent of the 
sample had a very high MPR and 20% had a low MPR. Overall, 30.7% had a treatment 
interruption. MPR decreased significantly as number of unique prescriptions increased 
(p=0.002). Patients with high cancer complexity had a lower MPR (p=0.003). Female 
patients had a lower MPR (p=0.003) than male patients. Higher rates of emergency room 
visits and urgent care use were found in patients with low MPRs. MPR was not 
associated with total healthcare costs including imatinib after adjusting for other factors 
(p=0.08), but was associated with total healthcare costs excluding imatinib (p<0.001). A 
10% decrease in MPR was associated with a 14% increase in medical and prescription 
costs, excluding imatinib costs, and 15% increase in medical costs.
19
  
Patridge et al. conducted an adherence study of anastrozole using longitudinal 
pharmacy and claims data from two large commercial health plans and MarketScan, an 
employer-based database.
109
 Patients with MPR greater than 80% were defined as 
adherent. Moreover, they also conducted a persistency analysis to identify patterns of 
prescriptions filled in nonadherent patients. Nonpersistent (i.e. discontinued) was defined 
as failure to fill prescriptions over a continuous 4-month period.  
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A total of 12,391 patients were included in the study. The mean MPR of 
patients in the 12 month follow-up group was between 82%-88%. The mean MPR 
declined after the first year of therapy.  In patients with 36 month follow-up, the MPR 
decreased from 78%-86% in year 1 to 62%-79% in year 3. The mean MPR in 
nonadherent patients was 42% in the first 12 months of therapy. The average gap 
between consecutive fills was 20 days. Of 184 patients with nonadherence, 76% were 
nonpersistent and the discontinuation rate was 13% during the first 12-months period.
109
 
Sedjo and Devince examined risk factors for nonadherence to three aromatase 
inhibitors (exemestane, anastrozole, and letrozole) using data from the MarketScan 
Commercial Claims and Encounters Database.
110
  Females enrolled for at least two years 
during the study period (January 1, 2005 to December 31 2007) and who had a claim for 
a primary or secondary breast cancer diagnosis in the first year were included in the 
study. Adherence was defined as an MPR greater than or equal to 80%. Multivariate 
logistic regression was used to determine the relationship between adherence and 
potential predictors that included “age, initial aromatase inhibitor treatment claim in 
2006, switching to another AI or tamoxifen, previous endocrine treatment, total OOP 
prescription costs, total medical OOP cost, mail order pharmacy use, outpatient visits, ER 
and/or urgent care use, oncology visit, mastectomy, and any use of a preventive health 
visit cancer diagnosis other than breast”110 Overall, the prevalence of nonadherence to AI 
treatment was 23%. Younger age, OOP cost greater than or equal to $30 per AI 
prescription, switching to another AI or tamoxifen, no mastectomy, and higher Charlson 
Comorbidity Index significantly increased the likelihood of nonadherence.
110
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A clinical trial was conducted by Noens et al. to assess the prevalence of 
imatinib nonadherence over a 90-day period among patients with CML.
27
  A prospective, 
observational multicenter noninterventional study was designed to examine the factors 
associated with nonadherence and to assess whether treatment response was associated 
with adherence levels. Treatment response was defined using hematologic cytogenetic 
and molecular response rates. Nonadherence was measured using self-report: “Basel 
Assessment of Adherence Scale (BAAS) with Immunosuppressive Medication adapted to 
imatinib.”27 Given a positive answer to any of the 4-questions on the adapted BAAS, a 
patient was defined as nonadherent. Pill count for a 90-day period was used to identify 
the “percent not taken of percent prescribed.”27 
A total of 169 patients were included. Nonadherence based on the BAAS was 
reported at 32.7% at the follow-up compared with 36.1% at baseline. On average, 
patients with suboptimal response had a higher mean percentage of not taking imatinib 
(23.2%, S.D. =23.8) compared with patients with optimal response (7.3%, SD=19.3; 
p=.005).  For patients treated with imatinib for at least 12 months, patients with complete 
cytogenetic response (CCyR) had a significantly lower mean percentage of not taking 
imatinib (9%, S.D. = 18.6) than those with incomplete response (26.0%, S.D. = 24.4; 
p=0.012). In all patients and those with at least 18 months of therapy, no significant 
difference was found in the mean percentages of pill count between complete and 
incomplete hematologic response patients.
27
 
Marin et al. conducted a study to examine the relationship between imatinib 
adherence and degree of molecular response in CML patients.
28
  Eighty-seven patients 
with CML who received imatinib as first therapy for at least 2 years were included in the 
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study. All patients had achieved complete cytogenetic response at the time of recruitment. 
Patients were required to tolerate at least 400 mg of imatinib. However, if patients failed 
to achieve major molecular response (MMR), the dose was increased to 600 mg. 
Adherence was measured using microelectronic monitoring system (MEMS) and blood 
sample test. MEMS was used to monitor adherence in patients for a median of 91 days 
(range 84 to 120 days). Logistic regression was used to determine the relationship 
between adherence and prognostic factors and the response in patients. The median 
adherence rate was 97.6% (range 22.6%-103.8%). Adherence was significantly 
associated with prior MMR achievement (RR, 1.093, p<0.001). The median adherence 
rate was significantly lower for patients who took the 600 mg dose than patients who 
remained on 400 mg (86% vs. 98.8%, p=0.21). Younger patients were more likely to 
have lower adherence rate than older. Other conditions associated with lower adherence 
rate included asthenia, nausea, muscle cramps, and bone or joint pain. The results of this 
group of studies indicated that nonadherence to oral cancer medications was between 3%-
41%. Low adherence was associated with negative consequences, including increased 
inpatient and non-cancer drug costs, higher number of inpatient and emergency room 
visits and inpatient days, and higher total health care costs. Factors found to be 
significantly associated with low adherence included high OOP costs, higher numbers of 
comorbidities, polypharmacy, and cancer complexity.
28
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Summary of Literature Review 
Overall, the review of literature indicates that high OOP costs of oral cancer 
drugs decrease patients’ adherence. Other factors that have been found to be associated 
with adherence include variation of pharmacy benefit design and cost-sharing structure. 
The findings from previous studies also indicate that patients with cancer experienced a 
high prevalence of nonadherence and could be at higher risk for cost-related 
discontinuation. 
Many studies have been conducted using pharmacy claims data from employer-
based insurance plans, private health insurance plans and managed care. These studies 
found rates of nonadherence to cancer medicines that ranged from 19 to 41%. The 
beneficiaries in these plans are, for the most part, under 65 years of age. Medicare data, 
or other data on elderly patients, have rarely been used to estimate adherence in oral 
cancer drug users. Another group of studies has measured patient adherence to oral 
cancer drugs in clinical trials. Rates of nonadherence in these studies ranged from 3 to 
33%.  Nonadherence rates from those studies may not accurately represent adherence to 
oral cancer drugs in real world medical practice because patients in trials are closely 
monitored and treated in a more controlled environment. Further, patients using oral 
cancer drugs in actual practice may have high OOP costs for these agents and this may 
increase the likelihood of nonadherence.  
Overall, as this review indicates, there has been a limited amount of research on 
costs of oral cancer drugs, especially in the Part D population. Similarly, there have been 
few published studies focusing on nonadherence to oral chemotherapy due to cost.  
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Our study was the first to examine the costs associated with the use of oral 
cancer medication and the impact of OOP costs and prescription drug coverage on 
medication discontinuation in a nationally representative Medicare Part D elderly 
population. 
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CHAPTER 3 
RESEARCH OBJECTIVES  
 
Objective1: To identify demographic characteristics and types of prescription drug 
subsidies for Part D beneficiaries who used oral cancer drugs in 2008 
 
Objective 2: To identify total costs, patient out-of-pocket costs, and plan costs relating to 
use of oral cancer medications in elderly Medicare Part D population in 2008 
 
Objective 3: To determine the percentage of patients entering the Medicare Part D 
coverage gap, the time they entered the gap in 2008, and the duration of time they spent 
in the gap in 2008. 
 
Objective 4: To determine the number and percentage of Medicare Part D patients who 
discontinued or delayed their oral cancer drug therapy in 2008. 
 
Objective 5: To examine the extent to which total out-of-pocket costs for oral cancer 
medications are associated with the discontinuation or delay of oral cancer medications, 
adjusted for factors associated with medication nonadherence including, polypharmacy, 
prescription drug subsidies, and socio-demographic factors.
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CHAPTER 4 
METHODS 
 
This chapter describes the methods used in conducting this study. It provides the 
complete details of all procedures performed in this study, including study design, sample 
preparation, and statistical analyses. In this chapter, the methods will be presented for 
each objective. 
Study Design 
This study was a cross-sectional retrospective study of spending on oral cancer 
drugs in the Medicare Part D population. All statistical analyses were performed with 
SAS software version 9.3 (Cary, NC).
 
Data and Sample Preparation 
The data used in this study were selected from the 2008 Medicare Part D database 
compiled by the Centers for Medicare and Medicaid Services (CMS) provided by the 
Research Data Assistance Center (ResDAC). A 5% random sample of 2008 Medicare 
beneficiaries was used. The sample included the Beneficiary Summary File with Part D 
denomination, Beneficiary Annual Summary File, Part D Event File with drug 
characteristics, and the Plan Characteristics File.
111
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The Beneficiary Summary File 
The Beneficiary Summary File with Part D denomination contains demographic 
eligibility and Part D enrollment information about beneficiaries who are eligible for 
Medicare. Table 1 shows the variables utilized from this file. 
Table 1: Variables from the Beneficiary Summary File
112,113
 
Variable SAS Variable Name Description 
Beneficiary ID   BENE_ID A unique encrypted 
beneficiary identification 
number 
The BENE_ID is used to link 
data for each beneficiary 
across all claim and 
assessment data files. 
State code  STATE_CD State of residence of a 
beneficiary 
Zip code of residence BENE_ZIP Zip code of residence based 
on the mailing address of a 
beneficiary. Each code is 
represented by a 9-digit code. 
Gender SEX Gender  
Race RACE Beneficiary race code 
Date of birth BENE_DOB Date of birth of the 
beneficiary 
Date of death BENE_DOD Date of death of the 
beneficiary 
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Cost share group CST_SHR_GRP_CD_01 – 12 Beneficiary’s cost-sharing for 
each month. This code 
indicates subsidy and dual 
eligible status of the 
beneficiary. 
Retiree drug subsidy RDS_CVRG_MOS_NUM Retiree drug subsidy coverage 
months number 
Dual eligible months 
number 
DUAL_ELGBL_MOS_NUM Total number of months of 
dual eligibility for each 
beneficiary 
Plan coverage 
months number 
PLAN_CVRG_MOS_NUM Total number of months of 
Part D plan coverage  
 
 
The Beneficiary Annual Summary File (BASF)  
The BASF provides diagnosis and date of diagnosis of 21 chronic conditions. 
This file was used to identify whether beneficiaries had any comorbidities while they 
received chemotherapy and to identify the history of any indications of cancer of each 
enrollee. However, only five selected cancers are on this list. Table 2 presents all 
variables utilized from the BASF file. This file was linked with the Beneficiary Summary 
File by using beneficiary identification number (BENE_ID). 
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Table 2: Variables used to identify beneficiaries’ comorbidities and history of any caner 
conditions
112,113
 
SAS Variable Name Description 
AMI CCW: Acute Myocardial Infarction 
ALZH CCW: Alzheimer’s Disease  
ALZHDMTA CCW: Alzheimer’s Disease and Related Disorder 
ATRIALFB CCW: Atrial Fibrillation  
CATARACT CCW: Cataract 
CHRNKIDN CCW: Chronic Kidney Disease 
COPD CCW: Chronic Obstructive Pulmonary Disease 
CHF CCW: Heart Failure  
DIABETES CCW: Diabetes  
GLAUCOMA CCW: Glaucoma 
HIPFRAC CCW: Hip/Pelvic Fracture  
ISCHMCHT CCW: Ischemic Heart Disease  
DEPRESSN CCW: Depression 
OSTEOPRS CCW: Osteoporosis 
RA_OA CCW: Rheumatoid Arthritis/Osteoarthritis 
STRKETIA CCW: Stroke / Transient Ischemic Attack 
CNCRBRST CCW: Female Breast Cancer 
CNCRCLRC CCW: Colorectal Cancer 
CNCRPRST CCW: Prostate Cancer 
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CNCRLUNG CCW: Lung Cancer 
CNCRENDM CCW: Endometrial Cancer  
CNCRBRSE Earliest indication of Female Breast Cancer  
CNCRCLRE Earliest indication of Colorectal Cancer  
CNCRPRSE Earliest indication of Prostate Cancer  
CNCRLNGE Earliest indication of Lung Cancer  
CNCENDME Earliest indication of Endometrial Cancer  
*CCW- Chronic Condition Data Warehouse is a research database providing Medicare, 
Medicaid, Assessment, and Part D prescription drug event data    
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Part D Event (PDE) File 
(1) Drug event and characteristics file  
     The Part D event (PDE) data, including the Drug and Plan Characteristics Files 
provide information on demographics and characteristics of drug, plan, and payment. 
Both drug and plan characteristic files were linked by using the encrypted beneficiaries’ 
identification number (Bene_ID) variable. Table 3 presents the variables obtained from 
the drug event and characteristics file. This file was used to identify the details of 
prescriptions, the payment amount for each fill, and to identify whether patients 
discontinued their oral cancer medication.   
Table 3: Variables used from drug characteristics file
112,113
  
SAS Variable Name Description 
BENE_ID Encrypted Beneficiary ID 
SRVC_DT Prescription service date 
QTY_DSPNSD_NUM Quantity dispensed 
DAYS_SUPPLY_NUM Number of days’ supply of medication dispensed 
PTNT_PAY_AMT Patient paid amount 
OTHR_TROOP_AMT Third party payments that contribute to true out-of 
pocket amount 
CVRD_D_PLAN_PD_AMT Net amount the plan paid for covered Part D drugs 
BENEFIT_PHASE Benefit phase of the Part D event 
BN Brand name of the drug  
GNN Generic name of the drug  
STR Drug strength 
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(2) Plan Characteristics File 
We used the plan characteristics file to determine the Part D benefit structure. The 
types of benefit structures include defined standard, actuarially equivalent standard, basic 
alternative, and enhanced alternative. The defined standard benefit includes an initial 
deductible of $275, pre-ICL in which the patient pays 25% coinsurance, coverage gap in 
which the patient pays 100% coinsurance, and catastrophic phase in which the patient 
pays 5% coinsurance. The actuarially equivalent standard benefit includes the same 
deductible as the standard benefit, but offers different cost-sharing. The basic alternative 
structure includes a lower deductible than the standard benefit and uses tiered cost-
sharing for covered prescriptions. The enhanced alternative benefit offers coverage for 
some medications during the coverage gap, lower cost-sharing, or covers more 
medications than the standard benefit.
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Calculating Median Household Income 
Several studies show that income is one of the potential factors that indicate 
which patients would discontinue or not adhere to their medications.
88,89,100,104,114
  
Medicare Part D data do not provide beneficiaries’ incomes. Therefore, to estimate 
patients’ incomes we had to use a proxy variable. We used the median household income 
of the beneficiary's zip code of residence. We obtained the income information from      
the Zip Code Tabulation Areas (ZCTA) level geography 2000: Version 4 dataset.
115
     
The income data contained the beneficiary’s zip code and was calculated from the US 
Census 2000 data. The ZCTA median household income information was provided       
by age range. We used the median household income for householders aged 65-74 years 
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old and aged 75 years or older in 1999 dollars. The 1999 median household income in the 
zip code of residence was linked with the Medicare data set by using the 5-digit zip code 
of residence. The income data were converted to 2008 US dollar values by adjusting for 
inflation using the Consumer Price Index (CPI). 
 
Adjusting for inflation 
The Consumer Price Index (CPI) is commonly used to measure the average 
change in prices over a period of time for a market basket of consumer products and 
services.
116
 The percentage annual inflation rate is used to calculate the change in 
price.
116
 This study used median household income values from 1999. As a result, we 
needed to adjust the value of 1999 dollars to their 2008 value. Table 4 illustrates the CPI 
from 2000 to 2008.
117,118
 
Current dollars is a term used to describe income in the year that an individual 
received it. After adjusting for price changes, the value expressed in dollars is called real 
dollars, constant dollars, or real income.
119
 
The following section illustrates the adjustment for inflation and inflation 
adjusted income. 
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Calculation for inflation using CPI and inflation adjusted income  
(a) Inflation  rate 
The following formula was used for calculating the inflation rate by using CPI. 
  
                          
           
                            ………………….. (1) 
Where:  
i = Inflation rate (%) 
CPI Current year = Consumer Price Index at the given year  
CPI Base year      = Consumer Price Index at the base year 
 
Example: 
According to equation 1, the inflation rate for year 2000 was calculated as 
  
           
     
      
                                                     = 0.0335x100 
         = 3.35 % 
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(b)   Inflation adjusted  income 
To assess the value of income accurately, income should be adjusted for 
changes in the cost of living over time. For example, if we compare the median 
household income of $25,000 in 1999 with the 2001 median income of $26,000 without 
adjusting for inflation, it would appear to have increased. However, if we convert the 
1999 current dollars to 2001 real dollars, the adjusted income is $26,574. This indicates a 
decrease in income from 1999 to 2001.  
The following formula was used to calculate the adjusted household income. 
FV = PV (1+r)………………….. (2) 
Where: 
 FV (Future value) = Real dollars (Inflation adjusted income) 
 PV (Present value) = Current dollars (unadjusted income) 
 r = Decimal inflation rate   
Example: 
According to equation 2, the inflation adjusted income of $35,000 for year 2008 
was calculated as: 
 FV2008= PV1999 [(1+r2000)(1+r2001)(1+r2002) (1+r2003) (1+r2004) (1+r2005) (1+r2006) 
(1+r2007) (1+r2008)] 
           FV2008 =35,000 [(1+0.0335) (1+0.0280) (1+0.0161) (1+0.0223) (1+0.0270) 
(1+0.0335) (1+0.0328) (1+0.0283) (1+0.0384)] 
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  = 35,000 x 1.292 
 FV2008 = 45,220 
               The real dollars for the 1999 income of $35,000 in 2008 was $45,220 after 
adjusting for inflation rates. 
 
Table 4: Annual average Consumer Price Index Research Series (CPI-U-RS) using 
current methods all items: 1999-2008
117
 
Year CPI-U-RS index Decimal inflation  Inflation rate (%) 
1999 244.7 - - 
2000 252.9 0.0335 3.35 
2001 260.0 0.0280 2.80 
2002 264.2 0.0161 1.61 
2003 270.1 0.0223 2.23 
2004 277.4 0.0270 2.70 
2005 286.7 0.0335 3.35 
2006 296.1 0.0328 3.28 
2007 304.5 0.0283 2.83 
2008 316.2 0.0384 3.84 
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A modified income variable was created using cost sharing status information 
from the Beneficiary Summary File and the median household income adjusted to 2008 
dollars. The cost sharing status variable (cost share group code) indicated the subsidy 
status of each beneficiary. We used the subsidy eligibility status of each beneficiary as of 
January 2008 to create the modified income variable. This was possible because the 
Medicare program determines eligibility for subsidies for cost sharing and premiums 
based on beneficiaries’ income and financial resources.120,121 Table 5 shows the income -
as a FPL threshold - and financial resource limits for each type of subsidy. 
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Table 5:  Subsidy/Dual eligibility status and copayment amount
115,120-123
 
Cost 
share 
group 
code 
 Copayment Eligibility 
status 
Assets 
Limit* 
Annual 
Income 
percentage 
of Federal 
Poverty 
Level 
(FPL) 
01 Beneficiaries 
living in long term 
care is qualified 
with 100%  
premium subsidy 
and no copayment 
0 Full 
Dual/Full 
subsidy 
$2,000 
(individual) 
$3,000 
(couple) 
<100% 
02 Beneficiaries is 
qualified with 
100% premium 
subsidy and low 
copayment 
$3.10 Full 
Dual/Full 
subsidy 
$2,000 
(individual) 
$3,000 
(couple) 
<100% 
(56%-
100%) 
03 Beneficiaries is 
qualified with 
100% premium 
subsidy and high 
copayment 
$5.60 Partial 
Dual/Full 
subsidy 
$4,000 
(individual) 
$6,000 
(couple) 
100-135% 
04 Beneficiaries with 
LIS, 100% 
premium-subsidy 
and high 
copayment 
$5.60 Full 
subsidy 
Resources < 
$6,290 
(individuals) 
or < $9,440 
(couples) 
< 135% 
05 Beneficiaries with 
LIS, 100% 
premium-subsidy 
and 15% 
copayment 
15% Full 
subsidy 
Resources 
between 
$6,290-
$10,490 
(individuals) 
or $9,440-
$20,970 
(couples) 
<135% 
06 Beneficiaries with 
LIS, 75% 
premium-subsidy 
and 15% 
copayment 
15% Partial 
Subsidy 
Resources 
below 
$10,490 
(individuals) 
or $20,970 
(couples) 
135% - 
140% 
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Cost 
share 
group 
code 
 Copayment Eligibility 
status 
Assets 
Limit* 
Annual 
Income 
percentage 
of Federal 
Poverty 
Level 
(FPL) 
07 Beneficiaries with 
LIS, 50% 
premium-subsidy 
and 15% 
copayment 
15% Partial 
Subsidy 
Resources 
below 
$10,490 
(individuals) 
or $20,970 
(couples) 
140% - 
145% 
08 Beneficiaries with 
LIS, 25% 
premium-subsidy 
and 15% 
copayment 
15% Partial 
Subsidy 
Resources 
below 
$10,490 
(individuals) 
or $20,970 
(couples) 
145%- 
150% 
09 No premium-
subsidy nor cost 
sharing 
 No Subsidy Not 
Applicable 
≥ 150% 
*These resource limits excluded the burial expenses for $1,500 (individual) and $3,000 
(couple). 
 
According to the 2008 Department of Health and Human Services (HHS) 
Poverty Guidelines, the FPL was calculated based on the number of people in a family or 
household (shown in Table 6).
124
 We estimated income from the FPL by assuming two 
people in each household because that is the minimum number needed to make up a 
family household as defined by census.
125
 We used a weighting system method to 
estimate the income for patients in different subsidy groups as described below.  
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Table 6: 2008 Department of Health and Human Services Poverty Guidelines
124
 
Persons 
in Family or Household 
48 Contiguous 
States and D.C. 
Alaska Hawaii 
1 $10,400 $13,000 $11,960 
2 14,000 17,500 16,100 
3 17,600 22,000 20,240 
4 21,200 26,500 24,380 
5 24,800 31,000 28,520 
6 28,400 35,500 32,660 
7 32,000 40,000 36,800 
8 35,600 44,500 40,940 
For each additional 
person, add 
3,600 4,500 4,140 
 
 
Estimation of modified income variable using FPL weighting 
We estimated the income for beneficiaries in each subsidy group by using the 
2008 HHS Poverty guidelines for two householders based on the state in which they 
resided. In 2008, the FPL for two people who lived in the contiguous 48 states and the 
District of Columbia was $14,000; in Alaska it was $17,500 and in Hawaii it was 
$16,100.  
Table 7 presents the calculation of the modified income variable using the 
weighting. Since the cost share group code was ranked by beneficiaries’ income levels, 
we weighted the FPL to estimate their incomes based on the code orders. Being eligible 
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for cost share group code 01 required that beneficiaries have annual incomes less than 
100% FPL, and resources less than $2,000 (individual) and $3,000 (Couple). In 2008, the 
income standard was $637 per month for an individual and $956 per month for a 
couple.
126
 This income standard for a couple was 82% of the FPL. As a result, we 
estimated these beneficiaries’ incomes as 82% of the FPL.122 
Beneficiaries in cost share group code 02 were required to have annual incomes 
less than 100% of the FPL. Financial eligibility standards for full dual eligibility vary 
significantly across states between 56% FPL in Connecticut and 109% FPL in Alaska.
127
  
However, these two values were only the maximum and minimum values. The majority 
of states set the eligibility at 75% FPL and 100 % FPL.
127
 As a result, we weighted the 
incomes of beneficiaries in this group as 87.5% of the FPL, which was the average of the 
income limit levels.  
Beneficiaries in cost share group code 03 were required to have annual incomes 
greater than or equal to 100%, but less than 135% FPL. There are several types of 
Medicare Savings Programs (MSPs) for partial dual eligible beneficiaries.
122
 These 
programs include Specified Low-Income Medicare Beneficiaries (SLMB) and Qualifying 
Individuals (QI). The SLMB require beneficiaries’ incomes being between the ranges of 
100-120% FPL and the QI require beneficiaries’ income between 120-135% FPL. We 
estimated the incomes of beneficiaries in this group with the average of the lower and 
upper income levels, which was 117.5% of the FPL.  
Beneficiaries in cost share group code 04 were required to have annual incomes 
less than 135% FPL and resources less than $9,440 (for couples). The resource limit for 
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these eligibility criteria was higher than the one for partial dual eligible beneficiaries. We 
weighted the income of beneficiaries who were in this group with 125% FPL.  
Beneficiaries in cost share group code 05 were required to have annual incomes 
less than 135% FPL and resources between $9,440 and $20,970 (for couples). Since the 
resource criteria for this group were higher than the previous group, we weighted the 
incomes of beneficiaries in this group with 130% of the FPL.  
Beneficiaries in cost share group code 06, 07, and 08 were required to have 
annual incomes in the ranges of 135-140%, 140-145%, and 145-150% of the FPL. Since 
the income levels were in ranges, we weighted beneficiaries’ incomes by using the 
average of the lower and upper limits.  
Lastly, since beneficiaries in cost share group code 09 were ineligible for a 
subsidy, there were no criteria for their income level limits. As a result, we assigned the 
median household income by the zip code of residence and age range as their incomes. 
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Table 7: Modified income variable for beneficiaries 
120-124
 
Cost 
share 
group 
code 
 Annual 
Income as a 
percentage 
of Federal 
Poverty 
Level (FPL) 
100% FPL for 2 people 
in household 
Generating modified 
income variable 
01 Beneficiaries 
qualified with 
100% premium 
subsidy and no 
copayment 
<100%  $14,000 (48states+D.C.) 
 $17,500  (Alaska) 
 $16,100  (Hawaii) 
 0.82x14,000 =$11,480 
 0.82x17,500 =$14,350 
 0.82x16,100 = $13,202 
02 Beneficiaries 
qualified with 
100% premium 
subsidy and low 
copayment  
< 100%  $14,000 (48states+D.C.) 
 $17,500  (Alaska) 
 $16,100  (Hawaii) 
 
 0.875x14,000 =$12,250 
 0.875x17,500=$15,313 
 0.875x16,100 = $14,088 
03 Beneficiaries 
qualified with 
100% premium 
subsidy and 
high copayment 
100%-135%  $14,000 (48states+D.C.) 
 $17,500  (Alaska) 
 $16,100  (Hawaii) 
 1.175x14,000 =$16,450 
 1.175x17,500 = $20,563 
 1.175x16,100 = $18,918 
 
04 Beneficiaries 
with LIS, 100% 
premium-
subsidy and 
high copayment 
< 135%  $14,000 (48states+D.C.) 
 $17,500  (Alaska) 
 $16,100  (Hawaii) 
 1.25x14,000 =$17,500 
 1.25x17,500 =$21,875 
 1.25x16,100= $20,125 
05 Beneficiaries 
with LIS, 100% 
premium-
subsidy and 
15% copayment 
<135%  $14,000 (48states+D.C.) 
 $17,500  (Alaska) 
 $16,100  (Hawaii) 
 1.30x14,000 = 18,200 
 1.30x17,500=22,750 
 1.30x16,100= 20,930 
06 Beneficiaries 
with LIS, 75% 
premium-
subsidy and 
15% copayment 
135% - 
140% 
 $14,000 (48states+D.C.) 
 $17,500  (Alaska) 
 $16,100  (Hawaii) 
 1.375 x14,000=19,250 
 1.375 x17,500=24,063 
 1.375 x16,100=22,138 
07 Beneficiaries 
with LIS, 50% 
premium-
subsidy and 
15% copayment 
140% - 
145% 
 $14,000 (48states+D.C.) 
 $17,500  (Alaska) 
 $16,100  (Hawaii) 
 1.425x14,000=19,950 
 1.425 x17,500= 24,938 
 1.425 x16,100=22,943 
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08 Beneficiaries 
with LIS, 25% 
premium-
subsidy and 
15% copayment 
145%- 
150% 
 $14,000 (48states+D.C.) 
 $17,500  (Alaska) 
 $16,100  (Hawaii) 
 1.475x14,000=20,650 
 1.475 x17,500=25,813 
 1.475 x16,100=23,748 
09 No premium-
subsidy nor cost 
sharing 
≥ 150% - Median household income 
by zip code and age range 
 
Study Sample 
The study examined the costs and use of the top selling five oral cancer drugs 
covered by Part D in 2008. These drugs included anastrozole (Arimidex
®
), imatinib 
(Gleevec
®
), letrozole (Femara
®
), erlotinib (Tarceva
®
), and thalidomide (Thalomid
®
).
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The sample included beneficiaries who met the following inclusion criteria: 
 65 years of  age or older at the beginning of  2008 
 Enrolled in Medicare Part D program for the entire 12-month period from January 
1, 2008 through December 31, 2008 
 Did not die by the end of 2008 
 Filled at least one of the above mentioned oral cancer medications 
We further excluded beneficiaries who met the following criteria from the 
samples used for the regression analyses (Objective 5): 
 Lack of data available for all variables used in the analyses. For example, income 
and coverage. 
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 Started filling the prescription after June 30th, 2008. We included only 
beneficiaries who started filling their prescriptions in the first six months of 2008 
to ensure that we had at least six months to identify medication discontinuation.  
 Male Beneficiaries who used anastrozole and letrozole. 
 Diagnosed with breast cancer by January 1, 2004 (anastrozole and letrozole only) 
 Switched between anastrozole and letrozole 
 
Figure 2 illustrates the selection of the sample and dataset preparation for the 
analyses. Beneficiaries were divided into five subgroups based on their oral cancer 
medication use:  imatinib, erlotinib, anastrozole, letrozole, and thalidomide. 
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Figure 2: Flow diagram for identifying the sample 
 
 
 
 
 
 
 
 
             Exclusions 
 
 
 
 
 
 
 
 
 
 
 
 
5% Beneficiary Annual Summary File 
N=2,631,825 (patients) 
5% Beneficiary Summary File 
N=2,631,860 (patients) 
5% Part D Event File 
N=58,382,553 (prescriptions) 
All Data linked 
N= 59,601,859 (patient-
prescription pairs) 
Imatinib users 
N=338 
- Non-elderly 2 months to 64.9 years old as of 
January 1, 2008) 
- Died by the end of 2008 
- Not enrolled in Part D for the entire year 
- Had incomplete data 
- Male beneficiaries (anastrozole and letrozole 
only) 
  
 
Anastrozole users 
N= 6,303 
Erlotinib users 
N= 335 
Thalidomide users 
N=222 
Letrozole users 
N=3,260 
 
61 
 
This section presents the methods used to conduct the analyses for each objective.  
Objective 1: 
The first objective was to identify the demographics and prescription drug 
subsidy status of Part D beneficiaries who used oral cancer drugs. 
The demographic characteristics of all oral cancer drug users were identified for 
each drug. The ages of beneficiaries were reported as means, ranges, and standard 
deviations. The gender and race of beneficiaries were reported in terms of frequency 
counts and percentages. We identified and reported the frequency counts and percentages 
of the type of prescription drug subsidies of all beneficiaries who used oral cancer drugs. 
The types of prescription drug subsidies included Medicaid and Medicare dual eligibility; 
low income subsidy (LIS): partial and full subsidies; and no subsidy. 
Objective 2: 
The second research objective was to identify the OOP cost and plan liability 
for oral cancer medications in the Medicare Part D program in 2008. OOP costs are the 
expenditures that enrollees were required to pay for their prescriptions excluding their 
premiums. The OOP cost was the sum of deductibles, cost sharing during the initial 
coverage phase, full cost of the drugs during the coverage gap, and 5% coinsurance 
during the catastrophic phase. Plan liability is the total expenditures for each beneficiary 
that plans were responsible for paying. Descriptive statistics were used to report the 
range, mean, median, and standard deviation of costs. 
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We examined the mean costs that patients paid per day, the costs that plans paid 
per day, and total OOP costs for the entire year for each drug. The variables utilized to 
calculate costs relating to oral cancer use included prescription filled date (SRVC_DT), 
days supply (DAYS_SUPPLY_NUM), the amount that patients paid OOP 
(PTNT_PAY_AMT), the amount that third party paid that contributed to true out-of 
pocket (OTHR_TROOP_AMT), and the amount that Part D plans paid 
(CVRD_D_PLAN_PD_AMT). 
We included only beneficiaries who filled a prescription between January 1, 
2008 and June 30, 2008 in our sample. The patients who received third party payments 
that contributed to OOP amount were excluded. We calculated the costs for each strength 
of each medication. However, the differences between the average wholesale prices 
(AWP)
128
 of the 100 mg and 150 mg strengths of erlotinib and the 100 mg, 150 mg, and 
200 mg strengths of thalidomide were very small. Because of this, and to increase the cell 
sample sizes for these combinations, we combined observations for these strengths of 
each of these drugs when calculating costs.   
1) OOP cost 
The OOP cost for each beneficiary was calculated as a daily cost. The cost was 
calculated using the patient paid amount (PTNT_PAY_AMT) and days supply variables 
(DAYS_SUPPLY_NUM). Total OOP cost was the sum of the total amount patients paid 
for their OOP divided by the total days supply. We calculated the total annual OOP cost 
by multiplying the daily cost by 365. 
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2) Plan liability 
Plan liability for each beneficiary was calculated based on the total costs that 
plans were responsible for paying per beneficiary per day. The cost was calculated by 
summing the total Part D plans paid amount (CVRD_D_PLAN_PD_AMT) divided by 
the total days supply (DAYS_SUPPLY_NUM). We calculated the annual plan cost by 
multiplying the daily cost by 365. 
Objective 3 
The high cost of oral cancer drugs could lead to patients quickly falling into the 
coverage gap. Therefore, the third objective of this study was to determine the percentage 
of beneficiaries who entered the coverage gap, to identify when beneficiaries fell into the 
gap, and to identify the length of time they stayed in the gap.  
We first assessed the percentage of patients who entered the Medicare Part D 
coverage gap. All beneficiaries who fell into the coverage gap - regardless of whether 
they stayed in the coverage gap or entered the catastrophic phase - were included in this 
analysis. The variable used to identify the coverage gap entry was the benefit phase of the 
prescription drugs event (BENEFIT_PHASE). This variable indicates the benefit phase 
based on the beneficiary's accumulated expenses. Some pharmacy claims overlapped 
between phases; for example, the first fill of a prescription that cost $1,000 would take 
the patient through the deductible phase and into the ICL phase. Prescription fills that are 
part of more than one benefit phase are called the straddle PDEs. 
The benefit phase variable includes ten codes: deductible phase (DD), 
deductible to Pre-ICL straddle PDE (DP), deductible to ICL straddle PDE (DI), 
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deductible to catastrophic straddle PDE (DC), Pre-ICL phase (PP), Pre-ICL to ICL 
Straddle PDE (PI), Pre-ICL to catastrophic straddle PDE (PC), ICL phase (II), and 
catastrophic phase (CC). We categorized the codes into 1) Deductible phase, 2) Pre-ICL 
phase, 3) ICL or coverage gap phase, and 4) catastrophic coverage phase. We collapsed 
the benefit phase into four categories based on the Part D standard benefit phases. In our 
collapsed categories, we categorized the benefit phase based on the last digit of the 
benefit phase variable code.
129
  The last digit of the code represented the benefit phase 
where beneficiaries fell at that fill. After recoding, the deductible phase included the code 
of DD; the Pre-ICL phase included the codes DP and PP: and the ICL phase contained 
DI, PI, and II. The catastrophic phase included DC, PC, IC, and CC. Frequency counts 
and percentages of enrollees who entered the coverage gap were reported. 
Next we identified when patients entered the coverage gap in 2008. We 
determined how long it took each patient to enter the coverage gap from the date that his 
or her initial prescription was filled. We identified the amount of time it took to reach    
the coverage gap in terms of months. The numbers and percentages of patients who 
entered the coverage gap each month were reported.    
Finally, we identified the duration of time spent in the coverage gap. We 
calculated the average duration of time that patients spent in each benefit phase, 
including: deductible, pre-ICL, ICL, and catastrophic phases. Means and standard 
deviations were reported. 
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Objective 4 
We identified the number and percentage of patients who discontinued or 
delayed therapy during 2008. Medication discontinuation or delay was defined as at 
least a 30 day delay for a scheduled refill.
130,131
  We identified patients who discontinued 
their medication, as those who had a gap of at least 30 days between the time the patient 
should have run out of medication, based on the time of his/her last refill, and the time 
he/she obtained the next refill (or December 31, 2008 if it was the patient’s last fill of 
the year). Discontinuation was defined as the patient being without medication for at 
least 30 days and not having another refill during the study period. Delay was identified 
from the gap as the period of time between the date that the patient's supply of the 
medication expired and the date that the patient obtained the next refill. Beneficiaries 
who delayed could resume refilling their prescription after the delay. 
  We identified the total number of beneficiaries who discontinued or delayed 
their therapy in each benefit phase. Frequency counts and percentages were reported for 
each drug. 
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Objective 5 
 The last objective was to examine the association between total OOP expenditures 
and medication discontinuation or delay, as adjusted for polypharmacy, prescription drug 
subsidies, and socio-demographic factors. 
Several studies have indicated that cost is one of the reasons that patients 
discontinued or did not adhere to their medication.
67,68,132-134
 According to these studies, a 
patient with high OOP spending has a higher risk of drug discontinuation.
70,132,133
 
We performed multinomial logistic regression to examine whether OOP 
spending was associated with oral cancer medication discontinuation or delay. We 
included patients who started filling their prescription in the first six months of 2008, so 
that we would have a sufficient number of patients and amount of time to determine 
patients’ discontinuation of medication. Medication discontinuation or delay was the 
outcome or dependent variable and was coded as 1 for delay and 2 for discontinuation. 
Otherwise, medication continuation was coded 0. The analysis included potential 
predictors that were available in the dataset that could influence medication 
discontinuation or delay. 
National Comprehensive Cancer Network (NCCN) guidelines recommend using 
anastrozole or letrozole as adjuvant endocrine therapy for five years.
79 
 Therefore, to 
ensure that delay or discontinuation was not from completion of treatment, we included 
only anastrozole and letrozole users who were diagnosed with breast cancer since January 
1, 2004. In addition, patients who switched between letrozole and anastrozole were 
excluded.    
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Logistic regression provided the odds of discontinuation or delay for every $1 
increase in OOP per month. We calculated the odds of discontinuation or delay for 
increase in total OOP costs per $10 and $100 by raising the odds ratio to the 10
th
 power 
or 100
th
 power, respectively. 
For example: 
Odds of discontinuation for every $1 increase in OOP cost = 1.005 
Odds of discontinuation for every $10 increase in OOP cost = 1.005
10 
Odds of discontinuation for every $100 increase in OOP cost = 1.005
100 
The following section presents the independent variables that were in the model. 
a) OOP costs 
We used OOP cost per month as a primary predictor in the regression analyses. 
The variables we used to calculate OOP costs included the amount that patients paid OOP 
for their medication costs (PTNT_PAY_AMT) and days supply (DAYS_SUPLY_NUM). 
The OOP costs were calculated based on types of discontinuation: delay, 
discontinuation, or continuation.  
1.) Delay: We defined the gap as the period of time between the date that the 
patient's supply of the medication expired and the date that the patient obtained the next 
refill. The OOP cost was calculated as the total OOP costs that the patient paid until the 
last claim before the delay. This was divided by the total days supply for the period 
before the delay. 
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2) Discontinuation: we defined discontinuation as prescriptions were filled 
consecutively every month but had discontinued by the end of 2008. A gap of 30 days or 
greater between the date that the patient's supply of the medication expired and 
December 31, 2008 was determined as discontinuation. We calculated OOP costs by 
summing total OOP costs that the patient paid until the last claim divided by the total 
days supply. 
Otherwise, all OOP costs for oral cancer drugs that a patient paid were summed 
and divided by the total days supply that they had the prescriptions filled for. We 
calculated monthly OOP costs by multiplying by 30.  
The following three examples illustrate how we calculated the OOP costs used 
in the analyses for delay, discontinuation, and continuation. 
Case 1 (Delay) 
A patient filled their prescriptions each month, consecutively, for a 30-day 
supply of their medications. However, the gap between the second and third fills was 
greater than 30 days. (The gap is defined as the period of time between the date that the 
patient's supply of the medication expired and the date that the patient obtained the next 
refill.) The OOP cost per day was calculated as the total OOP costs that the patient paid 
until the last claim before the delay. This was divided by the total days supply for the 
period before the delay. That is, we included all OOP costs that the patient paid for the 
first and second prescription divided by total days supply for the first and second 
prescription. The patient could resume his/her therapy any time after the delay. However, 
we considered this patient as a delay because effective chemotherapy requires that the 
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patient strictly follow the regimen and continue the treatment. This is especially 
important for long term chemotherapy. Table 8 shows the fill dates and OOP costs for a 
patient who delayed filling their prescription and later resumed therapy.  
 
Calculation 
OOP cost per month = (OOP costs for 1
st
 fill +2
nd
 fill) x 30/ (total days supply) 
                           = ($2,250 +$1,750) x 30/ (30+30) 
            OOP cost = $2,000 per month  
 
Table 8: Fill dates and OOP costs for a patient who delayed filling their prescription 
between fills 
Rx 
Fill date 
Days 
supply 
Expected next fill 
date 
OOP 
Cost ($) 
1
st
 January 15, 2008 30 February 14, 2008 2,250 
2
nd
 February 12, 2008* 30 March 13, 2008 1,750 
3
rd
 May 18, 2008 30 June 17, 2008 156 
4
th
 
June 18, 2008 30 July 18, 2008 156 
Rx= Prescription, OOP =Out-of-Pocket cost 
* February had 29 days in 2008  
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Case 2 (Continuation) 
A patient filled their prescription consecutively every month for 12 times in 
2008 (Table 9). This patient was defined as a continuation. We calculated the OOP cost 
for this patient as shown below. 
Calculation 
OOP cost per month = (OOP costs for 1
st
 +2
nd
 +3
rd
 +4
th
 +5
th
 +6
Th
 +7
th
 +8
th+ 
9
th
+ 10
th
 + 
11
th
 +12
th
 fills) x 30/ (total days supply) 
                                   = ($2,595+$1,320+159+159+159+159+159+170+170+170+ 
170+170) x 30/ (12x30) 
         OOP cost = $463.3 per month  
Table 9: Fill dates and OOP costs for a patient who filled oral cancer prescription 
drug consecutively. 
Rx Fill date 
Days 
supply 
Expected next fill 
date 
OOP 
Cost ($) 
1
st
 January 25, 2008 30 February 24, 2008 2,595 
2
nd
 February 23, 2008* 30 March 24, 2008 1,320 
3
rd
 March 23, 2008 30 April 22, 2008 159 
4
th
 April 20, 2008 30 May 20, 2008 159 
5
th
 May 20, 2008 30 June 19, 2008 159 
6
th
 June 20, 2008 30 July 20, 2008 159 
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7
th
 July 19, 2008 30 August 18, 2008 159 
8
th
 August 17, 2008 30 September 16, 2008 170 
9
th
 September 17, 2008 30 October 17, 2008 170 
10
th
 October 17, 2008 30 November 16, 2008 170 
11
th
 November 15, 2008 30 December 15, 2008 170 
12
th
 December 15, 2008 30 - 170 
Rx= Prescription, OOP =Out-of-Pocket cost.  *In 2008, February had 29 days  
 
Case 3 (Discontinuation) 
A patient filled their prescription consecutively every month but had discontinued 
by the end of 2008 (Table 10). We defined the discontinuation here as a gap of more than 
30 days between the date that the patient's supply of the medication expired and 
December 31, 2008. We calculated OOP costs for these patients as shown below. 
Calculation 
OOP cost per month = (OOP costs for 1
st
 +2
nd
 +3
rd
 +4
th
 +5
th
 +6
Th
 +7
th
 +8
th+ 
9
th
 fills) x 30/  
(total days supply) 
                                   = ($2,690+$1,350+163+163+163+163+174+174+174) x 30/ (9x30) 
                  OOP cost = $579.3 per month  
 
 
 
72 
 
Table 10: Fill dates and OOP costs for a patient who filled oral cancer prescription 
drug consecutively but discontinued by the end of 2008. 
Rx 
Fill date 
Days 
supply 
Expected next fill 
date 
OOP 
Cost ($) 
1
st
 February 13, 2008* 30 March 14, 2008 2,690 
2
nd
 March 13, 2008 30 April 12, 2008 1,350 
3
rd
 April 12, 2008 30 May 12, 2008 163 
4
th
 May 11, 2008 30 June 10, 2008 163 
5
th
 June 10, 2008 30 July 10, 2008 163 
6
th
 July 10, 2008 30 August 9, 2008 163 
7
th
 August 8, 2008 30 September 7, 2008 174 
8
th
 September 7, 2008 30 October 7, 2008 174 
9
th
 October 7, 2008 30 November 7, 2008 174 
Rx= Prescription, OOP =Out-of-Pocket cost 
*February had 29 days in 2008.  
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b) Polypharmacy 66,88,102 
We measured polypharmacy by counting the number of concurrent medications 
that patients were taking during treatment. We used generic drug names (GNN) to count 
the total number of unique prescription drugs. Polypharmacy may cause adverse events 
and increase patients’ prescription costs leading patients to discontinue or delay their oral 
chemotherapy.  
c) Comorbidities88 
The total numbers of chronic conditions that patients had were included in the 
analyses. We identified chronic conditions that patients had from the variables provided 
by the CCW dataset.
112,135
 These variables included Alzheimer’s disease (ALZH), acute  
myocardial infarction (AMI), Alzheimer’s disease or senile dementia (ALHDMTA), 
atrial fibrillation (ATRIALFB), cataract (CATARACT), chronic kidney disease 
(CHRNKIDN), chronic obstructive pulmonary disease (COPD), depression 
(DEPRESSN), diabetes (DIABETES), glaucoma (GLAUCOMA), heart failure (HF), 
hip/pelvic fracture (HIPFRAC), colorectal cancer (CNCRCLRC), endometrial cancer 
(CNCRENDM), breast cancer (CNCRBRST), lung cancer (CNCRLUNG), prostate 
cancer (CNCRPRST), ischemic heart disease (ISCHMCHT), osteoporosis (OSTEOPRS), 
rheumatoid arthritis/osteoarthritis (RA_OA), and stroke/transient ischemic attack 
(STRKETIA). Chronic conditions were determined based on information obtained 
through Fee-for-Service (FFS) administrative claims data, including International 
Classification of Diseases Ninth Revision (ICD-9-CM), Current Procedural Technology 
(CPT-4) 4
th
 edition, and Healthcare Common Procedure Coding System (HCPCS). Each 
variable had four values: 0 = neither claims nor coverage met; 1= claims met, coverage 
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not met; 2 = claims not met, coverage met; and 3 = claims and coverage met. Patients 
with value of 1 and 3 were determined to have chronic conditions because they indicated 
whether a beneficiary received services in 2008.
135
   
d) Drug subsidy status 132,133 
Drug subsidy status was included in the model as an indicator variable. It was 
coded as 1 to indicate the patient received a subsidy (DE, full LIS, or partial LIS) and 0 
for no subsidy.   
e) Drug benefit type88 
This variable indicates the type of Part D benefit structure, including 1) defined 
standard benefit, 2) actuarially equivalent standard, 3) basic standard, and 4) enhanced 
alternative. The variable was included in the model as a categorical variable. 
f) Income88,114 
A proxy income variable was created and included in the analyses. The details 
of generating the income variable were described previously in the data preparation 
section. 
g) Total OOP costs for other non-cancer prescription drugs 
We calculated the total OOP costs for other medications that patients were 
taking concurrently during oral cancer drug treatment until oral cancer medication 
discontinuation or delay. We determined total OOP costs for other medications in the 
same process that we calculated OOP spending for oral cancer drugs.  
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h) Mental status 88 
We created binary variables that identified patients who had Alzheimer’s 
disease or depression condition. We used the variables of Alzheimer’s disease (ALZH) 
and senile dementia (ALHDMTA) indicating Alzheimer’s disease and were coded as 1. If 
patients had depression (DEPRESSN), they were coded as 1, otherwise as zero. 
 
i) A history of cancer 
A dummy variable was created as to indicate whether the patient was previously 
diagnosed with any of the cancer conditions included on the Part D dataset. The cancer 
conditions included colorectal cancer (CNCRCLRE), endometrial cancer 
(CNCENDME), breast cancer (CNCRBRSE), lung cancer (CNCRLNGE), and prostate 
cancer (CNCRPRSE). The variable of diagnosed dates of the earliest indication of cancer 
was used to identify whether patient had been diagnosed with any of these cancers before 
2008. The previously diagnosed cancer variable was assigned a value of 1 if the 
beneficiary had been diagnosed with cancer and 0 if they had not been diagnosed. 
 
j) Patient demographic variables 26,88,130 
Gender and race variables were included in the analyses. Female and white race 
variables were used as referent groups. Age was generated from the patients’ dates of 
birth. 
The age variable was created based on the tertiles of age for each drug and 
incorporated as a categorical variable in the analyses. The categories were based on 
boundaries at the 33
th
 and 66
th
 percentiles of the distribution (Table 11). 
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Multicollinearity is a common problem in multivariate regression. 
Multicollinearity occurs when predictors are correlated. This could become a serious 
problem and it could provide inaccurate results and large standard errors for the 
estimation.
136,137
 We determined collinearity by checking the variance inflation factor 
(VIF) for all independent variables. If a VIF for one of independent variables is greater 
than 4, it indicated a strong collinearlity between that variable with others. As a result, we 
removed it from the analysis. For any two or more variables with a VIF greater than 4, 
we checked the correlations among those variables. If the high correlations were detected, 
the intercorrelated variables must be removed from the analysis.  
 
 
Table 11: Tertile categories of age
 
      Medication 
Tertile 
Imatinib 
(years) 
Erlotinib 
(years) 
Thalidomide 
(years) 
Anastrozole 
(years) 
Letrozole 
(years) 
1
st
 65.0-71.49 65.0-72.90 65.0-71.20 65.0-71.28 65.0-70.52 
2
nd
 71.50-78.43 72.91-79.16 71.21-77.60 71.29-78.70 70.53-77.88 
3
rd
 >78.43 >79.16 >77.60 >78.71 >77.88 
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CHAPTER 5 
RESULTS 
 
This chapter presents the results for each objective.  
Objective 1: To identify demographic characteristics and prescription drug coverage of Part D 
beneficiaries who used oral cancer drugs in 2008.  
Overall, beneficiaries who used oral cancer medications had mean ages between 
74 and 76 years. Over half of oral cancer medication users were Caucasian and female. 
Over two-thirds of all oral cancer medication users received no subsidies for their 
prescription coverage. Approximately a quarter of all oral cancer medication users were 
dual eligible beneficiaries. No beneficiary in our sample received a retiree drug subsidy. 
More detailed information is shown in Table 12 and Table 13. 
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Table 12:  Type of prescription drug subsidy by medication 
Total (%) Imatinib 
(N=338) 
Erlotinib 
(N= 335) 
Anastrozole 
(N=6,303) 
Letrozole 
(N= 3,260) 
Thalidomide 
(N= 222) 
Dual eligible 
 
83     
(24.56) 
87 
(25.97) 
130 
   (20.75) 
696    
(21.35) 
54           
(24.32) 
Low Income Subsidy (LIS) 
 Full 
subsidy 
10(2.96) 10(2.99) 243 (3.86) 121(3.71) 9 (4.05) 
 Partial 
subsidy 
11(3.25) 2 (0.60) 118 (1.87) 53 (1.63) 3 (1.35) 
No Subsidy           
N (%) 
234   
(69.23) 
236 
(70.45) 
4,634   
(75.52) 
2,390    
(73.31) 
156        
(70.27) 
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Table 13: Demographic characteristics of beneficiaries by type of oral cancer 
medication used 
 Imatinib 
(N=338) 
Erlotinib 
(N= 335) 
Anastrozole 
(N=6,303) 
Letrozole 
(N= 3,260) 
Thalidomide 
(N= 222) 
Age       
   Mean (S.D.) 75.7 (6.83) 76.0(6.55) 76.04 (7.20) 75.9(7.04) 74.8 (6.40) 
   Range 65.2-97.2 65.0-96.0 65.0-105.7 65.0-98.8 65.0-94.5 
Gender      
  Male (%) 143 (42.31) 92(27.46) 50 (0.79) 19 (0.58) 101 (45.5) 
  Female (%) 195 (57.69) 243(72.54) 6,253 (99.21) 3,241 (99.42) 121 (54.5) 
Race        
  Unknown - - 6(0.1) 4(0.12) 1 (0.45) 
Caucasian (%) 267 (78.99) 269 (80.30) 5482 (86.97) 2,827 (86.72) 168 (75.68) 
 African-
American (%) 
37 (10.95) 29 (8.66) 519 (8.23) 276 (8.47) 34 (15.32) 
 Other (%) 7 (2.07) 8 (2.39) 78 (1.24) 41(1.26) 3 (1.35) 
 Asian (%) 15 (4.44) 20 (5.97) 80 (1.27) 36 (1.10) 5 (2.25) 
 Hispanic (%) 9 (2.66) 7 (2.09) 125 (1.98) 69 (2.12) 9 (4.05) 
Native 
American (%) 
3 (0.89) 2 (0.60) 13 (0.21) 7 (0.21) 2 (0.90) 
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Objective 2:  
To identify patient out-of-pocket and plan costs relating to use of oral cancer medications 
in the elderly Medicare Part D population in 2008 
We categorized oral cancer medication users in four categories: 1) Dual Eligible 
(DE), 2) full Low Income Subsidy (LIS), 3) partial LIS, and 4) no subsidy. The details of 
the costs for all cancer medications are shown in Tables 14 to Table 17. We included 
only beneficiaries who filled their first prescription during the first six months of 2008. 
As a result, the sample sizes for some combinations of drug, strength, and subsidy type 
were small or missing. 
Mean OOP costs per day were between $0.03 and $0.09 for DE beneficiaries, 
between $0.04 and $0.23 for full LIS beneficiaries, between $1.17 and $6.34 for partial 
LIS beneficiaries and between $2.93 and $36.84 for beneficiaries who did not receive a 
subsidy. 
Mean plan costs per day per beneficiary were between $4.67 and $140.44 for 
DE beneficiaries, between $4.52 and $177.36 for full LIS beneficiaries, between $4.39 
and $172.62 for partial LIS, and between $5.21 and $145.65 for beneficiaries who did not 
receive a subsidy. 
Table 18 shows details for annual patient costs and plan costs. 
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Table 14: Costs of oral cancer medications for dual eligible beneficiaries 
Costs($) Imatinib Erlotinib Thalidomide Anastrozole Letrozole 
 100 mg 
(N=27) 
400 mg 
(N=46) 
25 mg  
(N= 2 ) 
100, 150 mg 
(N =45) 
50 mg 
(N=14 ) 
100,150, 200 mg 
(N=32)` 
1 mg 
(N= 1,134) 
2.5 mg 
(N=597) 
OOP cost/day 
Mean  
(S.D.) 
0.08 
(0.24) 
0.03 
(0.03) 
0.08 
(0.04) 
0.05 
(0.05) 
0.04 
(0.04) 
0.05 
(0.05) 
0.09 
(0.06) 
0.09 
(0.07) 
Median ($) 0.03 0.02 0.08 0.03 0.03 0.04 0.09 0.10 
Range [0,1.28] [0, 0.12] [0.05,0.10] [0, 0.19] [0, 0.11] [0, 0.20] [0,0.65] [0, 1.04] 
Plan cost/day 
Mean  
(S.D.) 
71.69 
(40.14) 
95.85 
(37.28) 
74.64 
(26.54) 
81.44 
(23.75) 
111.97 
(58.22) 
140.44 
(49.60) 
4.67 
(1.53) 
5.00 
(1.76) 
Median 70.77 94.84 74.64 89.08 93.13 148.05 4.46 4.82 
Range [8.07,170.06] [5.31,203.04] [55.88,93.41] [17.59, 113.63] [38.08, 243.88] [59.87, 317.33] [0, 9.04] [0, 12.12] 
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Table 15: Costs of oral cancer medications for full low income subsidy beneficiaries 
Costs Imatinib Erlotinib Thalidomide Anastrozole Letrozole 
 100 mg 
(N= 1 ) 
400 mg 
(N=11 ) 
25 mg 
 (N= 0 ) 
100, 150 mg 
(N= 6) 
50 mg 
(N= 5) 
100,150, 200 mg 
(N= 4)` 
1 mg 
(N=216) 
2.5 mg 
(N=102) 
OOP cost/day 
Mean ($) 
(S.D.) 
- 0.07 
(0.06) 
- 0.12 
(0.07) 
0.10 
(0.09) 
0.04 
(0.04) 
0.23 
(0.48) 
0.21 
(0.41) 
Median ($) - 0.05 - 0.08 0.06 0.03 0.16 0.19 
Range - [0.03,0.19] - [0.03, 0.19] [0.01, 0.20] [0, 0.10] [0.03, 3.74] [0.03, 3.81] 
Plan cost/day 
Mean 
(S.D.) 
- 76.70 
(25.82) 
- 68.84 
(23.81) 
177.36 
(116.60) 
161.92 
(37.28) 
4.52 
(1.56) 
4.79 
(1.69) 
Median - 89.60 - 74.63 218.52 174.83 4.22 4.52 
Range - [25.54, 96.50] - [36.24, 92.31] [46.72, 294.90] [107.28, 190.76] [0, 10.85] [0.88, 9.10] 
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Table 16: Costs of oral cancer medications for partial low income subsidy beneficiaries 
Costs Imatinib Erlotinib Thalidomide Anastrozole Letrozole 
 100 mg 
(N=  4) 
400 mg 
(N=6 ) 
25 mg  
(N= 0) 
100,150 mg 
(N= 1) 
50 mg 
(N= 2) 
100, 150, 200 
mg 
(N= 1)` 
1 mg 
(N=92) 
2.5 mg 
(N=40) 
OOP cost/day 
Mean ($) 
(S.D.) 
2.58 
(1.07) 
5.96 
 (5.82) 
- 6.34 
 
4.19 
(1.14) 
3.51 1.26 
(1.04) 
1.17 
(0.33) 
Median ($) 2.90 3.98 - 6.34 4.19 3.51 1.15 1.20 
Range [1.13, 3.39] [2.66, 17.74] - - [3.39, 5.0] - [0.34, 9.24] [0.06, 1.56] 
Plan cost/day 
Mean (S.D.) 81.40 
(40.81) 
85.53 
(15.12) 
- 87.28 148.56 
(38.33) 
172.62 4.39 
(1.56) 
5.35 
(1.85) 
Median 78.99 89.90 - 87.28 148.56 172.62 4.14 5.28 
Range [44.41,123.20 [55.88,97.56] - - [121.46, 175.67] - [0, 8.64] [1.60, 9.27] 
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Table 17: Costs of oral cancer medications for beneficiaries who did not receive a subsidy 
 Imatinib Erlotinib Thalidomide Anastrozole Letrozole 
 100 mg 
(N= 49 ) 
400 mg 
(N=97) 
25 mg  
(N= 11) 
100-150 mg 
(N=106) 
50 mg 
(N= 51) 
100,150, 200 mg 
(N= 60) 
1 mg 
(N=3,189) 
2.5mg 
(N=1,612) 
OOP cost/day 
Mean 
($) 
(S.D.) 
29.00 
(28.60) 
20.03 
(12.07) 
15.66  
(16.74) 
28.60 
(17.03) 
36.84 
(30.80) 
36.83 
(29.79) 
2.93 
(1.86) 
3.15 
(2.05) 
Median ($) 16.25 16.07 14.79 21.14 27.81 24.31 2.74 2.80 
Range [7.17,129.57] [4.04,73.32] [1.90,61.47] [2.67, 84.29] [5.49, 147.78] [8.08,129.29] [0.31, 9.74] [0.33, 10.36] 
Plan cost/day 
Mean 
(S.D.) 
69.92 
(26.64) 
93.78 
(27.82) 
74.73 
(38.83) 
81.94 
(19.24) 
108.24 
(81.12) 
145.65 
(49.75) 
5.21 
(1.69) 
5.75 
(1.92) 
Median 61.64 93.50 86.66 86.41 89.63 146.80 5.20 5.76 
Range [19.52,162.94] [12.02,203.56] [21.68,133.72] [22.68, 124.06] [29.93, 492.43] [52.53, 316.46] [0, 12.47] [0, 13.96] 
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Table 18: Estimated annual costs for all types of prescription drug subsidy 
Annual Cost 
($) 
Imatinib Erlotinib Thalidomide Anastrozole Letrozole 
100 mg 400 mg 25 mg 100-150 mg 50 mg 100,150,200 mg 1 mg 2.5 mg 
Dual Eligible 
Patient 29.20 10.95 29.20 18.25 14.60 18.25 32.85 32.85 
Plan 26,166.85 34,985.25 27,243.60 29,725.60 40,869.05 51,260.60 1,704.55 1,825.00 
Full Low Income Subsidy 
Patient - 25.55 - 43.80 36.50 14.60 83.95 76.65 
Plan - 27,995.50 - 25,126.60 64,736.40 59,100.80 1,649.80 1,748.35 
Partial Low Income Subsidy 
Patient 941.70 2,175.40 - 2,314.10 1,529.35 1,281.15 459.90 427.05 
Plan 29,711.00 31,218.45 - 31,857.20 54,224.40 63,006.30 1,602.35 1,952.75 
No Subsidy 
Patient 10,585 7,310.95 5,715.90 10,439.00 13,446.60 13,442.95 1,069.45 1,149.75 
Plan 25,520.80 34,229.70 27,276.45 29,908.10 39,507.60 53,162.25 1,901.65 2,098.75 
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Objective 3:  
To determine the number and percentage of patients entering the Medicare Part D 
coverage gap, the time that they entered the gap, and the duration of time spent in the gap 
(a) Number and percentage of patients entering the Medicare Part D coverage 
Gap 
Table 19 illustrates, by drug, the number and percentage of oral cancer 
medication users who entered the coverage gap. Approximately 99% of the beneficiaries 
who used imatinib, erlotinib and thalidomide entered the coverage gap. In contrast, 
approximately 70% of beneficiaries using the less expensive drugs (anastrozole and 
letrozole) entered the coverage gap. 
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Table 19: Number of patients who entered the Part D coverage gap by drug 
Medication Entered the Gap 
N (%) 
Did not enter the Gap 
N (%) 
Imatinib 
(N=288 patients) 
284 (98.61) 4 (1.39) 
Erlotinib 
(N=298 patients) 
295 (98.99) 3 (1.01) 
Anastrozole 
(N=5,585 patients) 
3964 (70.95) 1623 (29.05) 
Letrozole 
(N=2,902 patients) 
1,975 (68.06) 927(31.94) 
Thalidomide 
(N=  195 patients) 
194 (99.49) 1 (0.51) 
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(b) Time of Part D coverage gap entry 
A majority of beneficiaries who used costly medications - imatinib, erlotinib, 
and thalidomide - entered the coverage gap at the time of their first fill. In contrast, 
beneficiaries who filled anastrozole or letrozole entered the coverage gap later; less than 
7% entered the coverage gap in the first fill. 
Table 20 presents the time that beneficiaries entered the Part D coverage gap for 
each medication. 
 
(c) Duration of time spent in the Part D coverage gap  
We found that there were two patterns of time spent in each benefit phase. For 
costly medications, including imatinib, erlotinib, and thalidomide, beneficiaries spent 
approximately a month in the coverage gap. Most of their time was spent in the 
catastrophic phase. For less expensive medications, anastrozole and letrozole, the time 
that beneficiaries spent in the pre-ICL and ICL phases were four to five times greater 
than those of beneficiaries using expensive oral cancer drugs (Table 21). 
 
 
. 
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Table 20: Time of coverage gap entry 
Duration*  
(month) 
Imatinib 
 (N=288) 
N (%)** 
Erlotinib 
(N=298) 
N (%)** 
Thalidomide 
(N=195) 
N (%)** 
Anastrozole 
(N=5,585) 
N (%)** 
Letrozole 
(N=2,902) 
N (%)** 
   0*** 254 (89.44) 289 (97.97) 191 (98.45) 220(5.55) 127 (6.43) 
1 26 (9.15) 5 (1.69) 2 (1.03) 73(1.84) 52 (2.63) 
2 4(1.41) 1(0.34) 1 (0.52) 210 (5.30) 137 (6.94) 
3 - - - 495 (12.49) 267 (13.53) 
4 - - - 521 (13.14) 276 (13.98) 
5 - - - 612 (15.44) 300 (15.20) 
6 - - - 740 (18.67) 350 (17.73) 
7 - - - 487 (12.29) 256 (12.97) 
8 - - - 350 (8.83) 117 (5.93) 
9 - - - 163(4.11) 54 (2.74) 
10 - - - 64 (1.61) 28 (1.42) 
11 - - - 29 (0.73) 10 (0.51) 
Did not 
enter the 
coverage 
gap 
4 3 1 1,623 927 
 
*Duration is the time in months from the first prescription beneficiaries filled to the time 
that they entered the coverage gap.  
** %- presents the percentage of the total number of oral cancer drug users for each drug 
who entered the coverage gap 
***The patient entered the coverage gap at the time he or she filled the first prescription. 
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Table 21:   Mean time beneficiaries spent in each benefit phase   
 Imatinib Erlotinib Thalidomide Anastrozole Letrozole 
Benefit Phase Days 
(S.D.) 
Days 
(S.D.) 
Days 
(S.D.) 
Days 
(S.D.) 
Days 
(S.D.) 
Deductible 
 
30  - - 28.80  
(5.60) 
28.29  
(4.71) 
Pre-ICL 
 
29.30 
(8.83) 
15.93 
(10.32) 
28 (0) 156.68  
(72.73) 
147.64  
(71.10) 
ICL 
 
36.80 
(19.30) 
32.98  
(23.92) 
33.14  
(16.98) 
130.38  
(61.78) 
129.15  
(62.67) 
Catastrophic phase 244.55 
 (107.65) 
159.90 
(112.90) 
188.03 
(112.10) 
108.66  
(63.65) 
112.95 
(64.39) 
ICL =Initial Coverage Limit 
 
91 
 
Objective 4:  
To determine the number and percent of patients who discontinued oral cancer therapy 
The total number of beneficiaries who used oral cancer medication and 
discontinued or delayed their treatment was 97 (33.45%) for imatinib, 142 (47.65%) for 
erlotinib, 117 (60%) for thalidomide, 2,690 (48.15%) for anastrozole and 1,495 (51.52%) 
for letrozole. Table 22 presents the total number of oral cancer drug users who 
discontinued or delayed their therapy in each benefit phase. The highest percentage of 
patients who used imatinib, erlotinib, and thalidomide delayed or discontinued their 
therapies in the catastrophic phase. In contrast, the highest percentage of anastrozole and 
letrozole users delayed or discontinued filling their medications permanently during the 
pre-ICL phase and coverage gap.   
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Table 22: Total number of oral medication users who discontinued or delayed their 
therapy by benefit phase 
Benefit Phase Imatinib 
N (%)* 
Erlotinib 
N (%)* 
Thalidomide 
N (%)* 
Anastrozole 
N (%)* 
Letrozole 
N (%)* 
Deductible 
Delay - - - - - 
Discontinuation - - - 6 (0.11) 1 (0.03) 
Pre-ICL 
Delay - - - 152 (2.72) 87 (3.00) 
Discontinuation 3 (1.03) 1(0.34) 1 (0.51) 1,100 (19.69) 639 (22.02) 
ICL 
Delay 16(5.52) 1 (0.34) - 491 (8.79) 257 (8.86) 
Discontinuation - 35 (11.74) 18 (9.23) 768 (13.75) 418 (14.40) 
Catastrophic phase 
Delay 39 (13.45) 23 (7.72) 24 (12.31) 140 (2.51) 76 (2.62) 
Discontinuation 39 (13.45) 82 (27.52) 74 (37.95) 33 (0.59) 17 (0.59) 
Total 97 (33.45) 142 (47.65) 117(60.0) 2,690 (48.15) 1, 495 (51.52 
*% - presents the percentage of the total number of oral cancer drug users for each drug 
ICL= Initial Coverage Limit 
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Objective 5:  
To examine the association between OOP costs and medication discontinuation or delay 
We used multinomial logistic regression to examine the association between 
OOP costs and medication discontinuation or delay. The reference groups were the 
groups of beneficiaries who continued using the therapy for each drug. We controlled 
for all variables which were discussed previously in the methods section in the adjusted 
models.  
We had a small sample size and many variables included in the model.  We 
checked the events per variable (EPV) in drugs with a small sample size: imatinib, 
erlotinib, and thalidomide.
138
 A common rule of thumb indicates that a regression should 
include ten events (or observations) for each independent variable.
138
  The EPVs were 
5.8 for imatinib, 7.6 for erlotinib, and 7.3 for thalidomide.  Even though the EPVs were 
below the rule of thumb, they were, according to Vittinghoff’s and McCulloch’s study, 
within the acceptable level.
139
    
Table 23 and Table 24 show the unadjusted and adjusted logistic regression 
analyses comparison for each drug. We found a significant relationship between OOP 
costs and medication discontinuation or delay. The odds of discontinuation and delay 
significantly increased as OOP costs increased for all study drugs. In the adjusted models, 
the odds of medication discontinuation were 1.007 (p<0.0001) for imatinib users, 1.010 
(p =0.0002) for erlotinib users, 1.013 (p=0.0002) for thalidomide users, 1.009 (p<0.0001) 
for anastrozole users, and 1.006 (p=0.0348) for letrozole users.  The odds of delay were 
1.007 (p<0.0001) for imatinib users, 1.010 (p =0.0005) for erlotinib users, 1.013 
(p=0.0003) for thalidomide users, 1.010 (p<0.0001) for anastrozole users, and 1.008 
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(p=0.0133) for letrozole users. For every one dollar increase in OOP cost per month, the 
odds of medication discontinuation increased 0.7% for imatinib users, 1% for erlotinib 
users, 1.3% for thalidomide users, 0.9% for anastrozole users, and 0.6% for letrozole 
users. The increases in odds were similar for delays in therapy for imatinib, erlotinib, and 
thalidomide. For every one dollar increase in OOP cost per month, the odds of delay 
increased 1% for anastrozole users and 0.8% for letrozole users (Table 24).  
We calculated the increase in the odds of discontinuation and delay for every 
$10 and $100 increase in the total OOP cost per month. For each $100 increase in OOP 
cost, the odds of discontinuation increased 101% for imatinib, 170% for erlotinib, and 
264% for thalidomide users. The increases in odds were similar for delays in therapy. 
Moreover, for every $10 increase in OOP cost, the odds of discontinuation increased 9% 
for anastrozole users and 6% for letrozole users. For every $10 increase in OOP cost, the 
odds of delay increased 10% for anastrozole users and 8% for letrozole user (Table 25). 
As the number of non-cancer drugs a beneficiary used increased, the odds of 
discontinuation increased significantly for imatinib, thalidomide, anastrozole, and 
letrozole users. The number of non-cancer drugs increased the odds of delay for 
anastrozole and letrozole users. Surprisingly, the odds of discontinuation and delay 
decreased with higher OOP costs for other non-cancer drugs for all patients. Moreover, 
higher numbers of comorbidities significantly increased the odds of discontinuation in 
letrozole users, but decreased the odds of discontinuation in thalidomide and erlotinib 
users. The drug benefit type had a significant impact on letrozole and anastrozole users 
in increasing the odds of discontinuation in patients with less generous coverage.  
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We found multicollinearity between the prescription drug subsidy variable and 
OOP costs for imatinib, erlotinib, and thalidomide. As a result, the prescription drug 
subsidy variable was excluded from the analyses for these medications. The odds of 
medication discontinuation or delay decreased in anastrozole and letrozole users who 
received prescription drug subsidies. We found that Alzheimer’s disease, depression, 
previous history of cancer, age, gender, income, and race were not associated with 
medication discontinuation or delay. 
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Table 23: Unadjusted multinomial logistic regression of medication discontinuation or delay 
Predictor Discontinuation 
or delay 
Imatinib 
OR 
(p-value) 
(95% CI) 
 
Erlotinib 
OR  
(p-value) 
(95% CI)  
Thalidomide 
OR 
(p-value) 
(95% CI)  
Anastrozole 
OR 
(p-value) 
 (95% CI) 
Letrozole 
OR 
     (p-value) 
(95% CI)  
OOP cost    Discontinuation 1.001*  
(0.0011) 
[1.001,1.002] 
1.002* 
(<0.0001) 
[1.001,1.002] 
1.001* 
(0.0005) 
[1.001,1.002] 
0.992* 
(<0.0001) 
[0.991,0.994] 
0.994* 
(<0.0001) 
[0.992,0.995] 
 Delay 1.002*  
(<0.0001) 
[1.001,1.002] 
1.001* 
(0.0041) 
[1.000,1.002] 
1.001* 
(0.0030) 
[1.000,1.002] 
0.992* 
(<0.0001) 
[0.990,0.994] 
0.992* 
(<0.0001) 
[0.989,0.994] 
* Significant at 0.05 
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Table 24 : Multinomial logistic regression for medication discontinuation or delay 
Predictor Discontinuation 
or delay 
Imatinib 
OR 
(p-value) 
(95% CI) 
N= 227 
Erlotinib 
OR 
(p-value) 
(95% CI) 
N= 163 
Thalidomide 
OR 
(p-value) 
(95% CI) 
N =149 
Anastrozole 
OR 
(p-value) 
(95% CI) 
N=3,716 
Letrozole 
OR 
(p-value) 
(95% CI) 
N= 1,697 
 
OOP cost Discontinuation 1.007* 
(<0.0001) 
[1.004,1.009] 
1.010* 
(0.0002) 
[1.005, 1.016] 
1.013* 
(0.0002) 
[1.006, 1.021] 
1.009* 
(<0.0001) 
[1.005, 1.013] 
1.006* 
0.0348) 
[1.002, 1.012] 
 Delay 1.007* 
(<0.0001) 
[1.004,1.010] 
1.010* 
(0.0005) 
[1.004, 1.015] 
1.013* 
(0.0003) 
[1.006, 1.020] 
1.010* 
(<0.0001) 
[1.005, 1.014] 
1.008* 
(0.0133) 
[1.002,1.015] 
Male Discontinuation 0.635 
(0.3676) 
[0.237, 1.704] 
1.079 
(0.9074) 
[0.301, 3.863] 
1.361 
(0.6251) 
[0.395, 4.685] 
-  - 
 Delay 0.622 
(0.3841) 
[0.214, 1.811] 
1.514 
(0.6040) 
[0.316, 7.258] 
7.509* 
(0.0147) 
[1.485, 37.960] 
- - 
Black Discontinuation 2.569 
 (0.1144) 
[0.796, 8.289] 
0.917 
(0.9133) 
[0.192, 4.377] 
0.262** 
(0.0773) 
[0.059, 1.158] 
1.105 
(0.5496) 
[0.796, 1.535] 
1.096 
(0.7005) 
[0.687, 1.749] 
 Delay 1.387 
(0.6610) 
[0.321, 5.985] 
0.972 
(0.9791) 
[0.117, 8.059] 
0.209 
(0.1063) 
[0.031, 1.397] 
1.470* 
(0.0350) 
[1.028, 2.103] 
0.990 
(0.9716) 
[0.575, 1.705] 
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Other races Discontinuation 1.135 
(0.8583) 
[0.282, 4.573] 
0.360 
(0.1883) 
[0.079, 1.649] 
0.083* 
(0.0094) 
[0.013, 0.543] 
0.768 
(0.2277) 
[0.500, 1.180] 
0.956 
(0.8886) 
[0.510, 1.793] 
 Delay 2.935 
(0.1327) 
[0.721, 11.938] 
0.163 
(0.1510) 
[0.014, 1.938] 
0.239 
(0.2319) 
[0.023, 2.495] 
1.252 
(0.3284) 
[0.798, 1.965] 
0.757 
(0.4649) 
[0.358, 1.598] 
Age(T1) Discontinuation 0.436 
(0.1347) 
[0.147, 1.293] 
0.629 
(0.4540) 
[0.187, 2.118] 
0.627 
(0.5672) 
[0.127, 3.104] 
1.007 
(0.9495) 
[0.801, 1.267] 
0.735** 
(0.0768) 
[0.522, 1.034] 
 Delay 0.315** 
(0.0772) 
[0.088, 1.134] 
0.631 
(0.5378) 
[0.146, 2.733] 
0.675 
(0.6908) 
[0.097, 4.688] 
0.807 
(0.1157) 
[0.617, 1.054] 
0.680** 
(0.0561) 
[0.458, 1.010] 
Age(T2) Discontinuation 0.611 
(0.3781) 
[0.205, 1.827] 
0.883 
(0.8462) 
[0.251, 3.104] 
1.384 
(0.6554) 
[0.332, 5.778] 
0.865 
(0.1975) 
[0.693, 1.079] 
1.116 
(0.5109) 
[0.804, 1.549] 
 Delay 0.786 
(0.6877) 
[0.243, 2.542] 
0.218 
(0.1046) 
[0.035, 1.372] 
1.648 
(0.5802) 
[0.281, 9.667] 
0.740* 
(0.0217) 
[0.572, 0.957] 
0.795 
(0.2468) 
[0.540, 1.172] 
Drug benefit 
type 
Discontinuation 1.035 
(0.8743) 
[0.672, 1.595] 
0.853 
(0.5181) 
[0.526, 1.383] 
0.925 
(0.7466) 
[0.575, 1.488] 
1.173* 
(0.0025) 
[1.058, 1.301] 
1.183* 
(0.0376) 
[1.010, 1.386] 
 Delay 1.093 
(0.7257) 
[0.672, 1.595] 
1.049 
(0.8806) 
[0.562, 1.960] 
0.987 
(0.9648) 
[0.541, 1.800] 
1.194* 
(0.0050) 
[1.055, 1.351] 
1.047 
(0.6203) 
[0.873, 1.257] 
Comorbidities Discontinuation 0.955 
 (0.7376) 
[0.727,1.253] 
0.723** 
(0.0616) 
[0.515, 1.016] 
0.662* 
(0.0310) 
[0.455, 0.963] 
1.023 
(0.4911) 
[0.959, 1.091] 
1.113* 
(0.0325) 
[1.009, 1.229] 
 Delay 1.082 
 (0.6053) 
1.064 
(0.7650) 
0.732 
(0.1887) 
1.034 
(0.3697) 
1.085 
(0.1606) 
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[0.803,1.458] [0.709, 1.597] [0.460, 1.165] [0.961, 1.114] [0.968, 1.217] 
Income Discontinuation 1.000 
(0.1782) 
[1.00, 1.00] 
1.00 
(0.4247) 
[1.00, 1.00] 
1.00 
(0.5830) 
[1.00, 1.00] 
1.00* 
(0.0474) 
[1.00, 1.00] 
1.00 
(0.1492) 
[1.00, 1.00] 
 Delay 1.000 
(0.4034) 
[1.00, 1.00] 
1.00 
(0.8966) 
[1.00, 1.00] 
1.00 
(0.8701) 
[1.00, 1.00] 
1.00* 
(0.0317) 
[1.00, 1.00] 
1.00 
(0.8501) 
[1.00, 1.00] 
 
Cancer Discontinuation 1.516 
(0.4720) 
[0.488, 4.716] 
3.639 
(0.1069) 
[0.757, 
17.497] 
5.708** 
(0.0527) 
[0.980, 33.240] 
1.049 
(0.7282) 
[0.802, 1.371] 
1.021 
(0.9170) 
[0.687, 1.518] 
 Delay 1.331 
(0.6542) 
[0.381, 4.656] 
1.119 
(0.9081) 
[0.167, 7.512] 
3.694 
(0.2196) 
[0.459, 29.757] 
1.254 
(0.1658) 
[0.911, 1.725] 
1.144 
(0.5813) 
[0.709, 1.846] 
Alzheimer 
 
Discontinuation 1.097 
 (0.9294) 
[0.142, 8.441] 
1.798 
(0.5262) 
[0.293, 
11.044] 
0.333 
(0.3577) 
[0.032, 3.463] 
1.351 
(0.1242) 
[0.921, 1.984] 
0.980 
(0.9499) 
[0.525, 1.829] 
 Delay 1.482 
 (0.7055) 
[0.193, 11.394] 
0.596 
(0.7152) 
[0.037,9.627] 
1.095 
(0.9457) 
[0.080, 15.009] 
1.320 
(0.2049) 
[0.859, 2.026] 
0.649 
(0.2535) 
[0.309, 1.363] 
Depression Discontinuation 1.957 
(0.4105) 
[0.396, 9.675] 
0.837 
(0.8502) 
[0.131,5.332] 
1.375 
(0.7679) 
[0.166, 11.385] 
1.012 
(0.9453) 
[0.717, 1.430] 
0.851 
(0.5221) 
[0.519, 1.395] 
 Delay 2.485 
(0.3033) 
[0.439, 14.064] 
0.202 
(0.2557) 
[0.013, 3.181] 
4.376 
(0.2738) 
[0.311, 61.566] 
0.936 
(0.7437) 
[0.629, 1.393] 
1.146 
(0.6262) 
[0.662, 1.985] 
Polypharmacy Discontinuation 1.084* 
 (0.0144) 
1.073 
(0.1281) 
1.160* 
(0.0076) 
1.096* 
(<.0001) 
1.074* 
(<0.0001) 
100 
 
[1.016, 1.156] [0.980, 1.175] [1.040, 1.294] [1.076, 1.117] [1.047, 1.102] 
 
 Delay 1.051 
(0.1780) 
[0.978, 1.129] 
0.994 
(0.9160) 
[0.886, 1.115] 
1.062 
(0.3968) 
[0.925, 1.219] 
1.091* 
(<.0001) 
 [1.068, 1.114] 
1.085* 
(0.0008) 
[0.968, 1.217] 
Subsidy Discontinuation - - - 0.058* 
(<0.0001) 
[0.043, 0.080] 
0.048* 
(<.0001) 
[0.030, 0.077] 
 Delay - 
 
- - 0.117* 
(<0.0001) 
[0.082, 0.169] 
0.122* 
(<.0001) 
[0.071, 0.210] 
Costs of non-
cancer 
medications 
Discontinuation 0.999* 
 (<0.0001) 
[0.999, 1.000] 
 
0.998* 
(<0.0001) 
[0.998, 0.999] 
0.998* 
(<0.0001) 
[0.997, 0.999] 
0.998* 
(<.0001) 
 [0.997, 0.998] 
0.998* 
(<0.0001) 
 [0.997, 0.998] 
 Delay 0.999* 
(<0.0001) 
[0.999, 1.000] 
0.999** 
(<0.0001) 
[0.998, 0.999] 
0.998* 
(<0.0001) 
[0.99, 0.999] 
0.998* 
(<.0001) 
 [0.997, 0.998) 
0.998* 
(<0.0001) 
 [0.997, 0.998] 
 
Age (T1), (T2) = age (indicator variable) in 1
st 
tertile and 2
nd 
tertile (3
th
tertile-reference group); Alzheimer = patients had an 
Alzheimer’s disease; Cancer = had a previous history of cancer; Comorbidities = number of medical conditions; Depression = 
patients had depression condition; Subsidy = received a prescription subsidy (did not received a subsidy - reference group);  OR = 
Odds Ratio; OOP cost = Out-of-Pocket cost; Polypharmacy = number of other medications used;  95% CI =95% Confident Interval 
* Significant at 0.05; ** significant at 0.10 
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Table 25: Odds of discontinuation or delay for increase in total out-of-pocket costs per month
a
  
Predictor Discontinuation 
or delay 
Imatinib 
(Adjusted 
OR) 
 
Erlotinib 
(Adjusted OR) 
Thalidomide 
(Adjusted OR) 
 
Anastrozole 
(Adjusted 
OR) 
 
Letrozole 
(Adjusted OR) 
 
  Each $100 increase  Each $10 increase 
OOP cost Discontinuation 2.01 
 
2.70 
 
3.64 1.09 1.06 
 Delay 2.01 
  
2.70 
  
3.64 
  
1.10 1.08 
a
The odds of discontinuation or delay for increase in total OOP costs were calculated by raising the odds ratio to the 10
th
 power or 
100
th
 power.
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CHAPTER 6 
 DISCUSSION 
This chapter discusses the results, strengths and limitations of the study. It 
further presents implications of this study and suggests directions for future study.  
This study hypothesized that beneficiaries with higher OOP spending were 
more likely to discontinue or delay their medications. We identified discontinuation or 
delay as an instance in which the patient was more than 30 days overdue for a refill. 
Discontinuation was defined as situations in which beneficiaries did not receive another 
refill during the study period.  Delay was defined as situations in which they did receive 
another refill after the gap in therapy.   
We found a significant relationship between OOP costs and medication 
discontinuation or delay. The findings from the multinomial logistic regression showed 
that the odds of discontinuation or delay were higher at higher levels of OOP spending. 
The odds for discontinuation and the odds of delay for each $100 increase in OOP are as 
follows. For each $100 increase in OOP cost, the odds of discontinuation or delay 
increased 101% for imatinib, 170% for erlotinib, and 264% for thalidomide users. The 
odds of discontinuation were slightly lower than the odds of delay among anastrozole 
and letrozole users. For every $10 increase in OOP cost, the odds increased 9% for 
anastrozole users who discontinued and 10% for those who delayed, and 6% for 
letrozole users who discontinued and 8% for those who delayed.  
The results also indicated that between 33% and 60% of Medicare Part D 
beneficiaries who used oral cancer medication discontinued their treatment. Previous 
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studies have found nonadherence rates of 12%-33% for oral cancer therapy,
27,36,109,140-142
 
2%-40% for parenteral cancer drugs,
143-147
 and 7%-20% for chronic diseases.
16-18,148-154
 
In our findings, approximately 33% of total imatinib users discontinued or 
delayed their treatment. This finding was slightly higher than previous studies in which 
the nonadherence rates among CML patients who used imatinib were between 26%-
29%.
28,29,166
  However, these studies were clinical trials and a majority of imatinib users 
were male and younger than 65 years old. The mean OOP costs of imatinib treatment in 
our findings were between $600-$870 per month. The difference in our nonadherence 
rate and in those found in these studies could reflect the effects of high OOP costs, 
because patients in trials were not required to pay OOP for their medications. 
Our results showed the highest discontinuation rates among thalidomide users.  
Discontinuation rates were 60% among thalidomide users in our study. According to 
previous studies, the discontinuation rates due to intolerance in thalidomide usage were 
between 8%-15%.
155-158
  However, these studies were clinical trials and they reported 
that a majority of patients were male
158
 and younger than 65 years old.
155,158
  The 
difference in our higher rates and the discontinuation rates found in these studies may be 
due to the strong association between OOP costs and discontinuation. Patients in the 
previous studies did not pay OOP for their medications. Our results found the mean 
OOP costs for thalidomide treatment were approximately $1,100 per month. As a result, 
the high OOP cost could influence patients’ decision on discontinuing their therapies.  
We found a 48% rate of discontinuation in erlotinib users. Clinical trials have 
found 5%-10% discontinuation rates of erlotinib use due to its side effects.
159,160
  A 
majority of patients in previous studies were male and younger than 65 years old.
159,160
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The mean OOP costs of erlotinib treatment in our findings were between $470-$858 per 
month. Again, the higher rate found in our study could reflect the effects on high OOP 
costs. 
Discontinuation rates for anastrozole and letrozole in this study were 48% and 
52%, respectively. These rates were higher than those found in previous studies, where 
the discontinuation rates in patients with breast cancer who used oral cancer drugs ranged 
between 19%-31%
36,109,140,161,167
 and a majority of patients were younger than 65 years 
old.
36,109,140,161
  In our findings, the mean OOP costs per month were $88 for anastrozole 
and $95 for letrozole. Even if the OOP costs per month for anastrozole and leterozole 
were not high, we found the odds of discontinuation increased 7%-10% for every $10 
increase in OOP cost per month. These results revealed that OOP costs could have lead to 
the higher discontinuation rates in our study.  
The odds of discontinuation or delay among beneficiaries who used anastrozole 
and letrozole and who received any prescription drug subsidy were significantly lower 
than for those who did not receive subsidies. We also found that the number of non-
cancer medications that the patients were taking during cancer treatment and their costs 
had a significant impact on discontinuation. Surprisingly, higher costs of non-cancer 
medication decreased the odds of discontinuation and delay for all study drugs. However, 
the number of non-cancer drugs increased the odds of delay for anastrozole and letrozole 
users and increased the odds of discontinuation for all patients except erlotinib users.  
Comorbidities were associated with decreased odds of discontinuation in 
erlotinib and thalidomide users; however, the odds of discontinuation increased among 
letrozole users.
161
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The income variable used in our study was not associated with discontinuation, 
possibly because the measure we used was based on income in a zip code rather than the 
individual's actual income. Age, gender, race, Alzheimer’s disease and depression were 
not associated with medication discontinuation or delay.  
Beneficiaries in our study were 65 years and older, with the average ages were 
between 74 and 76 years. A majority of patients in our study were female. In previous 
studies, most oral cancer medication users were male and younger than 65 years old. 
Because of the differences in age and gender, the results from previous studies may not 
accurately compare with our sample. Moreover, the nonadherence rates from clinical 
trials were not able to represent the nonadherence to oral cancer drugs due to OOP costs 
because patients in previous studies did not pay high OOP costs.  
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Strengths and Limitations 
The strengths of this study are the following: 
 First, this study used prescription claims data from the Medicare Part D 
population. At this time, this is the first study to examine the costs relating to the use of 
oral chemotherapy and the impact of cost-sharing on the use of oral chemotherapy in the 
Medicare Part D population.  
 Second, the study results were nationally generalizable since this study used 
nationally representative Medicare claims data. The results were generalizable for oral 
cancer medication costs and adherence of Medicare cancer survivors across the United 
States. 
The limitations of this study include the following.  
First, the available data did not allow us to determine whether medication 
discontinuation occurred because patients discontinued their cancer treatment on their 
own or as a result of their physicians’ advice. Oral cancer drugs are self-administered 
outside providers' offices and are taken without close monitoring by physicians. As a 
result, patients could potentially stop their medications due to side effects associated with 
drugs.
47,67,161
  We did not have drug adverse event information in our dataset. As a result, 
we cannot identify whether beneficiaries discontinued their therapies because of high 
OOP costs or because of side effects of oral chemotherapy. However, we found that the 
rates of discontinuation in our study were higher than those found in clinical 
trials.
27,28,160,161,162 Given that patients in clinical trials do not pay OOP for their 
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chemotherapy, this suggests that at least some of the differences in discontinuation rates 
could be due to cost.   
Moreover, we lacked cancer stage information in the data. We did not know if 
patients were in the later or at the beginning stages of cancer. Late stage or severely ill 
patients might decide to stop their therapy and switch to palliative care. Moreover, late 
stage patients with high OOP payments might believe the treatment has less benefit to 
them and discontinue the therapy by themselves. 
Second, this study used only Part D data and did not have information about 
cancer drugs that were covered by Part B. Consequently, we were unable to determine the 
extent to which patients switched from oral medications to injections or the extent to 
which patients who received cancer drugs under both Part B and Part D continued their 
Part B medication without taking their Part D medication. This limitation should have 
only a limited impact on our results because the amount of switching between oral and 
parenteral therapy is not likely to be large. Most practice guidelines recommend 
prescribing intravenous drugs as the first-line therapy, Part D covered oral cancer drugs 
are used primarily as alternative or adjuvant treatment.
79,84,86
  In our study, docetaxel 
(injection) or pemetrexed (injection), and bortezomib (injection) are substitutes covered 
by Part B for erlotinib and thalidomide, respectively. However, docetaxel (injection) or 
pemetrexed are second line therapies for NSCLC and bortezomib is an alternative drug 
for maintenance therapy for multiple myeloma. 
Third, Medicare Part D data did not include personal income data, so median 
household income data by zip code were used as proxies for beneficiaries' household 
income. We attempted to increase the accuracy of the income variable by incorporating 
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the eligibility income limits for patients who received subsidies; however, this was not a 
good measure for beneficiaries’ incomes because it did not represent beneficiaries’ actual 
income.  
Fourth, this study was a cross-sectional design in which only 2008 Part D data 
were used. The impact of OOP spending should be investigated in the long-term to 
examine the outcomes of discontinuation and delay. Because we used only one year’s 
data, it is unable to determine whether beneficiaries that delayed or discontinued their 
therapy late in the year had completely discontinued or whether resumed therapy in the 
following year.    
Fifth, Medicare Part D enrollees who have a high demand for prescriptions may 
have strong incentives to enroll in plans with more generous coverage, and adverse 
selection could arise as a result.
164
  Beneficiaries who do not have any subsidy can switch 
their plan during the open enrollment period by the end of the year (October 15 to 
December 7, of each year). Only dual eligible or LIS beneficiaries can switch to a new 
plan any time during the year. In our study, all five medications are used in the long term. 
If beneficiaries were diagnosed with cancer and prescribed any of the oral drugs by the 
open enrollment period, they could switch to plans with more comprehensive coverage 
and pay higher premiums. However, this limitation should have limited impact on our 
discontinuation results because we used only one year of data and included only 
beneficiaries who filled oral cancer drugs in the first sixth months of 2008, which was 
immediately after the open enrollment period. As a result, the amount of switching to a 
new plan is not likely to be large. Subsidy patients would be unlikely to experience 
adverse selection because of the low OOP costs associated with the subsidies. 
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Sixth, we included only those beneficiaries who filled prescriptions in the first 
six months of the year to calculate the costs of oral cancer drug treatment. We had a small 
sample for a number of drug, strength, and subsidy type combinations. For example, we 
did not have any cost data for erlotinib 25 mg for beneficiaries who received subsidies 
and imatinib 100 mg for beneficiaries with full LIS.   
Moreover, according to the logistic regression assumptions,
165
 we could 
overspecify the confounders in the model because of the small sample size and the 
number of variables that we included to fit the model. We had fewer than 10 events per 
variable in our study, which violates the rule of thumb.
138
 However, the relative bias was 
within an acceptable level.
139
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Implications 
The findings of this study provide policymakers with estimates of the total 
annual OOP costs that patients pay for oral cancer drugs and of the substantial effects that 
these costs have on medication adherence. The time that patients enter the coverage gap 
and the duration of time they spend in the coverage gap affect OOP costs and, 
consequently, adherence.  
 From our findings, the cost of cancer treatment plays an important role in 
nonadherence. We found that high OOP costs increase the risk that patients will stop 
taking oral chemotherapy. This could result in progression or increased severity of 
disease, leading to hospitalization, mortality and increasing health care          
expenditures.
15,19-21
 Moreover, policymakers should be aware of the negative 
consequences of the Medicare Part D coverage gap. We found that a majority of cancer 
drug users entered the coverage gap in the first fill of their prescriptions, resulting in a 
significantly high discontinuation rate after they reached the coverage gap. Medicare Part 
D beneficiaries with higher OOP medication spending had higher rates of cost-related 
nonadherence. The Affordable Care Act provides expanded coverage for Medicare Part D 
beneficiaries such that the coverage gap will be fully closed by 2020. Part D beneficiaries 
will pay only 25% for covered prescriptions after meeting the deductible and before 
reaching the catastrophic phase.
165 
 OOP costs will be decreased, in the best case, to one-
fourth of the amount of OOP costs that the beneficiaries in this study paid. However, 
OOP costs will continue to be high, especially for beneficiaries using brand name 
medications without generic equivalents, because of the high cost of these products and 
the substantial coinsurance rates. Discontinuation could be the only choice for patients 
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who cannot afford the high costs of the therapy and lack lower-priced alternatives. 
According to our finding, for every $100 increase in the OOP cost, the odds of 
discontinuation increased 101%-264% for expensive oral cancer drug users. The 
increased likelihood of discontinuation will exist among beneficiaries on oral cancer drug 
treatment even after coverage gap is closed. 
Future Research 
Future research should study the effects of total OOP costs on adherence and 
discontinuation on a long-term basis. To detect the effects of high OOP spending over 
several years, a longitudinal study design should be employed. Medication 
discontinuation can be identified more accurately in a longer period of time, because it 
would provide enough time to examine if beneficiaries discontinued their therapies 
completely. Moreover, the time to discontinuation can be measured if the researchers 
have several years of data. In addition, the effects of OOP costs and medication 
adherence can be measured by examining medication possession ratios (MPR) or 
proportion of days covered (PDC) and the OOP costs. 
More research can be conducted to examine the OOP costs and nonadherence in 
cancer drugs by using both Part B and Part D data. OOP costs for cancer treatment could 
be compared between Part B and Part D covered drugs to identify the differences in OOP 
costs between the benefits or to compare the costs of oral therapy and parenteral therapy. 
Moreover the effects of OOP on adherence could be analyzed to examine the 
nonadherence due to high OOP costs and compare the extent and impact of OOP costs 
between Part B and Part D covered oral cancer drugs. Moreover, both Part B and Part D 
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data can be used to evaluate the extent of switching between parenteral and oral cancer 
therapy. The costs for oral and parenteral cancer therapy can be estimated to gain insights 
into the total costs relating to cancer treatment.  
Conclusions 
In conclusion, approximately 33-60% of total oral cancer drug users 
discontinued or delayed their therapies and most discontinued or delayed during the 
catastrophic phase. There was a significant association between OOP costs and 
medication discontinuation or delay. As OOP costs increased, the odds of medication 
discontinuation or delay increased. 
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